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A B S T R A C T
Background
Malaria caused by Plasmodium vivax requires treatment of the blood-stage infection and treatment of the hypnozoites that develop in
the liver. This is a challenge to effective case management of P vivax malaria, as well as being a more general substantial impediment to
malaria control. The World Health Organization (WHO) recommends a 14-day drug course with primaquine, an 8-aminoquinoline,
at 0.25 mg/kg/day in most of the world (standard course), or 0.5 mg/kg/day in East Asia and Oceania (high-standard course). This
long treatment course can be difficult to complete, and primaquine can cause dangerous haemolysis in individuals with glucose-6-
phosphate dehydrogenase (G6PD) deficiency, meaning that physicians may be reluctant to prescribe in areas where G6PD testing is
not available. This Cochrane Review evaluated whether more patient-friendly alternative regimens are as efficacious as the standard
regimen for radical cure ofP vivax malaria.
Objectives
To assess the efficacy and safety of alternative primaquine regimens for radical cure of P vivax malaria compared to the standard or
high-standard 14 days of primaquine (0.25 or 0.5 mg/kg/day), as well as comparison of these two WHO-recommended regimens.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register; the Cochrane Central Register of Controlled Trials
(CENTRAL); MEDLINE (PubMed); Embase (Ovid); and LILACS (BIREME) up to 17 December 2018. We also searched theWHO
International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov, and checked the reference lists of all studies identified
by the above methods.
Selection criteria
Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an
artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the
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same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0.25 or
0.5 mg/kg/day for 14 days), or a comparison of these two WHO-recommended regimens.
Data collection and analysis
Two review authors independently assessed trial eligibility and quality, and extracted data. We calculated risk ratios (RRs) with 95%
confidence intervals (CIs) for dichotomous data. We grouped efficacy data according to length of follow-up. We analysed safety data
where this information was included.
Main results
High-standard 14-day course versus standard 14-day course
Two RCTs compared the high-standard 14-day regimen with the standard 14-day regimen. People with G6PD deficiency and pregnant
or lactating women were excluded. We do not know if there is any difference in P vivax recurrences at 6 months with 0.5 mg/kg/day
primaquine therapy for 14 days compared to 0.25 mg/kg/day primaquine therapy for 14 days (with chloroquine: RR 0.82, 95%CI 0.47
to 1.43, 639 participants, very low-certainty evidence; with chloroquine or an ACT: RR 1.11, 95% CI 0.17 to 7.09, 38 participants,
very low-certainty evidence). No serious adverse events were reported. We do not know whether there is a difference in adverse events
with the higher dosage (very low-certainty evidence).
0.5 mg/kg/day primaquine for 7 days versus standard 14-day course
Five RCTs compared 0.5 mg/kg/day primaquine for 7 days with the standard 14-day course. There may be little or no difference in P
vivax recurrences at 6 to 7 months when using the same total dose (0.5 mg/kg/day to 210 mg) over 7 days as compared to 14 days (RR
0.96, 95% CI 0.66 to 1.39; 1211 participants; low-certainty evidence). No serious adverse events were reported. There may be little or
no difference in the number of adverse events known to occur with primaquine between the primaquine shorter regimen as compared
to the longer regimen (RR 1.06, 95% CI 0.64 to 1.76; 1154 participants; low-certainty evidence). We do not know whether there is
any difference in the frequency of anaemia or discontinuation of treatment between groups (very low-certainty evidence). Three trials
excluded people with G6PD deficiency, and two did not provide this information. Pregnant and lactating women were either excluded
or no details were provided regarding their inclusion or exclusion.
0.75 mg/kg primaquine/week for 8 weeks versus high-standard course
One RCT compared weekly primaquine with the high-standard 14-day course. G6PD-deficient patients were not randomized but
were included in the weekly primaquine group. Only one G6PD-deficient participant was detected during the trial. We do not know
whether weekly primaquine increases or decreases recurrences of P vivax compared to the 14-day regimen at 11 months’ follow-up (RR
3.18, 95% CI 0.37 to 27.6; 122 participants; very low-certainty evidence). No serious adverse events and no episodes of anaemia were
reported.
Three other RCTs evaluated different alternative regimens and doses of primaquine, but one of these RCTs did not have results available,
and two used regimens that have not been widely used and the evidence was of very low certainty.
Authors’ conclusions
Although limited data were available, the analysis did not detect a difference in recurrence between the 7-day regimen and the standard
14-day regimen of 0.5 mg/kg/day primaquine, and no serious adverse events were reported in G6PD-normal participants taking 0.5
mg/kg/day of primaquine. This shorter regimen may be useful in G6PD-normal patients if there are treatment adherence concerns.
Further large high-quality RCTs are needed, such as the IMPROV trial, with more standardised comparison regimens and longer
follow-up to help resolve uncertainties.
P L A I N L A N G U A G E S U M M A R Y
Primaquine to cure people with Plasmodium vivax malaria: comparing dosing schedules
Plasmodium vivax malaria can sometimes cause potentially life-threatening illness, and the infection continues to make many people
unwell. The infection includes a liver stage, and this requires primaquine to eradicate it and prevent the infection recrudescing. However,
the current dosing schedule requires 14 days of daily treatment.
What are the concerns about primaquine?
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Primaquine is the only drug currently recommended to treat the liver parasites in P vivax malaria. It can cause anaemia in people with
glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is a relatively common genetic blood disorder. Shorter regimens would
help reduce the risk of default with the current two-week regimen.
What does the research say?
We summarized trials that compared the World Health Organization (WHO)-recommended primaquine regimen of 15 to 30 mg per
day for 14 days with the same or higher doses of primaquine given over different lengths of time to determine whether alternative
regimens were as successful as the recommended courses at preventing future episodes of P vivax malaria. We searched for trials up to
17 December 2018, and included nine randomized controlled trials (studies in which participants are assigned to one of two or more
treatment groups in a random manner) in our analysis.
When using 30 mg per day compared to 15 mg per day primaquine therapy for 14 days, we do not know if there is any difference in
P vivax recurrences at 6 months (very low-certainty evidence). No serious side effects were reported, but it is unclear whether or not
there is a difference in other side effects between doses (very low-certainty evidence).
When using 30 mg primaquine per day for 7 days compared to 15 mg per day for 14 days, there may be no difference in P vivax
recurrences at 6 to 7 months (low-certainty evidence). No serious adverse events were reported. There may be no difference in the
number of side effects known to occur with primaquine between the two treatment regimens (low-certainty evidence).
We do not know whether weekly primaquine increases or decreases recurrences of P vivax compared to the 14-day regimen at 11
months’ follow-up (very low-certainty evidence).
Further large high-quality RCTs are needed, such as the IMPROV trial, to help improve the certainty of the evidence around alternative
regimens.
How up-to-date is this review?
The review authors searched for studies up to 17 December 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
0.5 mg/kg/day for 7 days versus standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with conf irmed clinical and parasitological P vivax malaria
Setting: India, Peru, Brazil
Intervention: 0.5 mg/ kg/ day primaquine for 7 days (adult dose 30 mg)
Comparison: standard 14-day course of primaquine (0.25 mg/ kg/ day, adult dose 15 mg)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard 14-
day course primaquine
Risk with 0.5mg/kg/
day primaquine for 7
days
Recurrence of P vivax
parasitaemia
Follow-up: range 6
months to 7 months
89 per 1000 86 per 1000
(59 to 124)
RR 0.96
(0.66 to 1.39)
1211
(4 RCTs)
⊕⊕©©
LOWa,b
Due to risk of bias and
imprecision
There may be lit t le or no
dif ference between 0.5
mg/ kg/ day primaquine
for 7 days and the stan-
dard 14-day course
Serious adverse ef fects See comment See comment - 1427
(5 RCTs)
- No events reported.
Adverse events that re-
sult in the discont inua-
t ion of treatment
3 per 1000 3 per 1000
(0 to 20)
RR 1.04
(0.15 to 7.38)
1154
(4 RCTs)
⊕©©©
VERY LOWc,d
due to risk of bias and
imprecision
We do not know if there
is any dif ference in ad-
verse events that result
in treatment discont in-
uat ion between 0.5 mg/
kg/ day primaquine for
7 days and the standard
14-day course
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Adverse ef fects known
to occur with pri-
maquine
44 per 1000 47 per 1000
(28 to 78)
RR 1.06
(0.64 to 1.76)
1154
(4 RCTs)
⊕⊕©©
LOWc,e
Due to risk of bias and
imprecision
There may be lit t le or
no dif ference in the
f requency of adverse
events known to oc-
cur with primaquine be-
tween 0.5 mg/ kg/ day
primaquine for 7 days
and the standard 14-
day course
Anaemia or change in
haemoglobin status
0 per 1000 0 per 1000
(0 to 0)
RR 3.0 (0.51 to 174.01) 240
(1 RCT)
⊕©©©
VERY LOWf,g,h
Due to risk of bias, in-
directness, and impre-
cision
We do not know if the
occurrence of anaemia
dif fers between the 2
treatment regimens
Adverse events known
to occur with chloro-
quine
0 per 1000 0 per 1000
(0 to 0)
RR 9.40
(0.51 to 174.01)
779
(1 RCT)
⊕©©©
VERY LOWi,j,k
Due to risk of bias, in-
directness, and impre-
cision
We do not know if
there is a dif ference in
the number of part ici-
pants experiencing ad-
verse events known to
occur with chlorquine
between the 2 treat-
ment groups
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once for risk of bias: Rajgor 2014 IND, which contributed the most weight to the meta-analysis, was at high risk
of select ion bias due to no allocat ion concealment and high risk of attrit ion bias. Although Pareek 2015 IND was at risk of
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select ion bias as well as other bias for being funded and carried out by drug company, it only contributed a small amount
of weight to the meta-analysis.
bDowngraded once for imprecision: wide CIs - may be 34% reduct ion in malaria recurrences or 40% increase with 0.5 mg/ kg/
day primaquine for 7 days.
cDowngraded once for risk of bias: Rajgor 2014 IND was at high risk of select ion bias due to no allocat ion concealment and
high risk of attrit ion bias. Pareek 2015 IND was at risk of select ion bias as well as other bias for being funded and carried out
by drug company.
dDowngraded twice for serious imprecision: very few events (only four events occurring in one trial, Rajgor 2014 IND), very
wide CIs.
eDowngraded once due to imprecision: wide CIs.
fDowngraded once due to risk of bias: Pareek 2015 IND was at risk of select ion bias and other bias (funded and performed
by drug company).
gDowngraded once for indirectness: only one study conducted in G6PD-normal adults in India (Pareek 2015 IND).
hDowngraded twice for serious imprecision: only one event, very wide CIs.
iDowngraded once for risk of bias: Rajgor 2014 IND at risk of bias select ion bias due to no allocat ion concealment and
attrit ion bias.
jDowngraded once for indirectness: only one study conducted in G6PD-normal adults in India (Rajgor 2014 IND).
kDowngraded twice for serious imprecision: few events, very wide CIs.
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B A C K G R O U N D
Malaria is a potentially life-threatening disease caused by the Plas-
modium parasite, which is transmitted by the bite of an infected fe-
male Anopheles mosquito. Five species of Plasmodium malaria par-
asites can cause malaria disease in humans, of which Plasmodium
vivax and Plasmodium falciparum are the most important (WHO
2016). In 2017, an estimated 219million cases ofmalaria occurred
worldwide and an estimated 435,000 people died from the disease
(WHO 2018). The World Health Organization (WHO) aims to
reduce malaria case load and mortality by at least 90% by 2030
(WHO 2016).
Historically, P vivax infection was thought to be a milder form of
malaria, and researchers have focused on P falciparum due to the
high number of deaths it causes (Bassat 2016). In recent years, it’s
been shown that the morbidity and mortality of P vivax have been
underestimated, with evidence of direct fatality and contribution
tomortality in patients who have other comorbidities, such asmal-
nutrition,HIV, or coexisting infections (Baird 2013; Bhattacharjee
2013;Rizvi 2013; Singh 2013; Battle 2014;Douglas 2014;Kochar
2014; Arévalo-Herrera 2015; Baird 2015b). Repeated P vivax in-
fections through childhood and adulthood also affect personal
well-being, development, and education and can thus negatively
impact economic development, both for the individual and the
community (Mendis 2001). P vivax malaria in pregnancy is as-
sociated with maternal anaemia, spontaneous abortion, stillbirth,
and low birthweight, with especially poor pregnancy outcomes
for women with severe infection (McGready 2012; Rijken 2012;
Brutus 2013).
Description of the condition
P vivax infection caused an estimated 7.5 million cases of malaria
in 2017 (WHO 2018). The geographical distribution ofP vivax
malaria is more widespread than any of the other forms of hu-
man malaria, with around 35% of the world’s population thought
to be at risk (Howes 2016) ). Co-infection with P falciparum is
also common in many regions (Kumar 2007; Mueller 2009). As
malaria control accelerates, the P vivax proportion in co-endemic
areas tends to rise compared to that of P falciparum, which high-
lights the importance and challenge of this infection (John 2012).
P vivax is important because as many countries progress towards
malaria elimination, the parasite becomes a roadblock to eradica-
tion (Cibulskis 2015; Bassat 2016). Despite a reported 45% re-
duction in P vivax malaria cases between 2010 and 2016 (WHO
2017), the parasite has several characteristics that enable it to evade
control (Newby 2016). The early appearance of gametocytes in the
blood, often prior to symptoms of malaria, increases the chance
of onward transmission by mosquitoes (Mendis 2001). P vivax
differs from P falciparum in that as well as having a blood-stage
infection, hypnozoites develop in the liver that can be dormant
for weeks to months before developing into an infection (White
2011). What triggers these relapses is not well-understood. There
is difficulty in distinguishing between relapse (hypnozoite activa-
tion), recrudescence (subpar treatment of the initial blood-stage
infection), and re-infection (new infection with P vivax) (Imwong
2007). A study in Papua NewGuinea suggested that relapses cause
four-fifths of P vivax infections (Robinson 2015), reinforcing the
importance of relapse in sustaining transmission (White 2011).
Parasites show high genetic diversity, even in countries that are at
malaria elimination stage (Koepfli 2015). P vivax is likely under-
estimated worldwide, as the dormant liver stage is not detected in
routine surveys (Gething 2012). Submicroscopic infections and
asymptomatic infection reservoirs may also lead to underdiagnosis
or misdiagnosis. A systematic review showed that across all study
sites, the polymerase chain reaction (PCR) prevalence of P vivax
was significantly higher than that identified by light microscopy
(Cheng 2015). The effect this may have on P vivaxmalaria studies
is unclear.
There are different strains of P vivax according to geographical
region/endemicity areas, with relapse patterns that vary by latency
(time to first relapse), likelihood of relapse, and frequency of re-
lapses, which further complicates the assessment of efficacy of
drugs on relapses (Battle 2014; White 2016). Strains commonly
found in Southeast Asia and Oceania (including the ‘Chesson’
strain isolated from an individual infected in Papua New Guinea)
have the shortest latency time to relapse, starting as early as three
weeks after first infection (if untreatedwith a hypnozoiticidal drug)
(Ehrman 1945). These areas correspond to zones 10 and 12 in
Battle 2014. Indian and Pakistan strains (zone 8) exhibit hetero-
geneity in relapse latency, incidence, and frequency, while South
American strains (zone 3) have a pattern of short latency to first
relapse and less frequent relapses than in zones 10 and 12 (Battle
2014). The temperate strains (which include those from Korea
in zone 11) relapse much more slowly (John 2012; Battle 2014).
Strains of the type in zones 10 and 12, referred to here as ’East
Asia and Oceania’, are recommended to receive higher doses of
primaquine (the high-standard course of 0.5 mg/kg/day rather
than standard 0.25 mg/kg/day for 14 days) to prevent relapses
(WHO 2015), apparently based on research done in the 1950s
and 1960s (Coatney 1953; Jones 1953; Vivona 1961;Maffi 1971;
Clyde 1977), although not all these studies were done with strains
from the targeted geographic area.
Primaquine, an 8-aminoquinoline, has until very recently been the
only drug available on themarket for treating the hypnozoite stage
of infection (Ashley 2014). One of the main barriers in P vivax
treatment is the reluctance to use primaquine due to it potentially
causing haemolysis in patients with glucose-6-phosphate dehydro-
genase (G6PD) deficiency. G6PD deficiency is the most common
enzyme deficiency worldwide and affects red blood cells by lead-
ing to their premature lysis (Nkhoma 2009). G6PD deficiency
is common in countries where P vivax malaria is endemic, with
an estimated population prevalence of 8% (Howes 2012). Within
G6PD deficiency, there are differing phenotypes, meaning some
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people may be mildly sensitive to primaquine, while others may
be very sensitive and experience life-threatening haemolysis (Baird
2015a), which explains the varying responses to primaquine. In
many areas where P vivax is predominant, testing for G6PD de-
ficiency is not available locally (Baird 2015b). In 2018 the US
Food and Drug Administration (FDA) approved a newer alter-
native, another 8-aminoquinoline known as tafenoquine (MMV
2018), which has shown promise in reducing relapses, but there
are increased safety concerns in patients with undiagnosed G6PD
deficiency compared to primaquine, due to its longer half-life
(Rajapakse 2015).
Description of the intervention
People with P vivaxmalaria require treatment with an antimalarial
drug to treat the blood-stage infection, and a drug to treat the
hypnozoite stage (radical cure). The WHO recommends treat-
ment with either chloroquine or an artemisinin-based combina-
tion therapy (ACT) for the blood-stage infection, with 0.25 to
0.5 mg/kg/day primaquine for 14 days for the liver stages (WHO
2015). Artemisinin-based combination therapies and chloroquine
have been shown to be effective and comparable in treating the
blood-stage infection of P vivax malaria (Gogtay 2013).
A previous Cochrane Review showed that primaquine regimens
of five days or fewer had similar recurrence rates to placebo or no
primaquine. Of the comparisons included in the review, a regimen
of 0.25mg/kg/day (15mg) a day of primaquine for 14 days had the
lowest recurrence rates of P vivax infection (Galappaththy 2013).
There were no trials at that time that compared higher doses of
primaquine at 14 or 7 days.
Primaquine was first made available to North American soldiers
in the 1950s (Baird 2004). Its mechanism and metabolism are
not widely understood, but it has a broad spectrum of activity
against the Plasmodium parasite. As well as preventing relapse of P
vivax malaria by targeting the latent and developing hypnozoites
in the liver, it is also used in malaria prophylaxis (Baird 2003). It
is absorbed from the gastrointestinal tract, has a half-life of about
four to nine hours, and crosses the placenta in pregnancy (Baird
2004). New advancements in studying P vivax in humanized mice
may lead to a greater understanding of the mechanism of action
of the drug (Mikolajczak 2015).
Adverse effects of primaquine include production of
methaemoglobin, an oxidated state of haemoglobin that cannot
transport oxygen to tissues. Methaemoglobinaemia (an abnormal
buildup of methaemoglobin) can result in cyanosis when levels ex-
ceed 10%of the usual haemoglobin level (Vale 2009). As described
above, primaquine causes haemolysis in people with G6PD defi-
ciency, which leads to anaemia (Ashley 2014). When taken on an
empty stomach it can cause abdominal pain and gastrointestinal
upset (Vale 2009). Safe use of primaquine during pregnancy has
not been established. The radical cure with primaquine can be de-
layed until after pregnancy. With regard to breastfeeding patients,
a recent study showed that the levels of primaquine in breast milk
may not be sufficient to cause haemolysis even in a G6PD-defi-
cient baby (Gilder 2018), but it is not recommended at this time.
How the intervention might work
The WHO advises that 0.25 mg to 0.5 mg/kg/day of primaquine
for 14 days should be used for radical cure of P vivax malaria
in patients over six months old, excluding people with G6PD
deficiency and those who are pregnant or breastfeeding (WHO
2015).
There has been suggestion of failure of the regimen of 0.25 mg/
kg/day for 14 days (hereafter referred to as the ’standard 14-day
regimen’) of primaquine for the Chesson strain of P vivax, which
was behind the suggestion of the increased dosing of 0.5 mg/kg/
day in East Asia and Oceania (hereafter referred to as the ’high-
standard 14-day regimen’). However, evidence for the choice of
the high-standard regimen is not presented in the WHO treat-
ment guidelines (WHO 2015). The previous Cochrane Review,
Galappaththy 2013, found no trials that compared the high-stan-
dard 14-day regimen to the standard 14-day regimen. The WHO
recommends a weekly dose of 0.75 mg/kg for eight weeks for pa-
tients with G6PD deficiency, but the evidence for this is of low
quality, as there are few high-quality trials (WHO 2015).
The 14-day course of primaquine can lead to treatment adherence
issues, as well as to safety concerns about haemolysis in places
where G6PD testing is not available, meaning that shorter courses
of primaquine are desirable. Failure to treat the hypnozoite stage of
P vivaxmalaria leads to repeated relapses,morbidity, and persistent
infection. The logic framework for developing efficacious and safe
treatment regimens for P vivax is illustrated in Figure 1.
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Figure 1. Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite activation.
It has long been suggested that it may be the total dose of pri-
maquine that is important in the treatment of the hypnozoite stage
rather than the length of the course (Schmidt 1977). If a higher
dose of primaquine could be administered safely over a shorter
period of time, it may improve adherence rates, thus reducing re-
lapse rates and morbidity and mortality resulting from P vivax
infection. There are small trials from the 1970s that suggest that
shorter, higher-dose regimens were as efficacious as the 14-day
courses (Clyde 1977; Saint-Yves 1977). At the time of the previous
Cochrane Review (Galappaththy 2013), there were no recent large
high-quality trials that had investigated the use of higher doses
given over seven days. We planned to include any such trials in
this Cochrane Review.
Why it is important to do this review
The use of primaquine for radical cure of P vivax malaria contin-
ues to pose a therapeutic dilemma for healthcare providers in areas
without adequate screening for G6PD status. Clinicians must ei-
ther choose to give primaquine and risk haemolysis if the patient is
G6PD-deficient, or withhold treatment and accept the complica-
tions of ongoing parasite infection and relapses. This is why when
clinicians choose to treat with primaquine they prefer a lower dose
over a more prolonged period, which then risks difficulties with
adherence and thus reduced effectiveness.
We know from the previousCochrane Review on primaquine with
chloroquine for radical cure that the standard 14-day regimen of
0.25mg/kg/day (15mgper day or 210mg total dose) is better than
shorter regimens of similar daily doses and placebo (Galappaththy
2013). In fact, the regimen of 0.25 mg/kg/day for 5 days of pri-
maquine did not reduce recurrences compared to treating with
chloroquine alone.
A major problem with the radical cure of P vivax is difficulty with
the adherence of the 14-day course of primaquine, which has led
to many countries shortening the regimen. Peru was one such ex-
ample, although a study revealed that patients often still discontin-
ued the therapy after around three days, when they started to feel
better (Grietens 2010). A study that compared directly observed
therapy (DOT) for 14 days of primaquine versus non-DOT pri-
maquine found that the P vivax recurrence rate was significantly
lower in the DOT group (Takeuchi 2010). These problems have
led to a more urgent call for shorter treatment regimens. Various
trials are investigating regimens that revise dosing and duration
of treatment in order to improve adherence and reduce the po-
tential for incomplete treatment and development of resistance.
As mentioned previously, the significance of the total cumulative
primaquine dose given, rather than the length of the course, is
one avenue of investigation. In areas where G6PD screening is
present, using higher dosing regimens over shorter time periods, if
at least similarly efficacious, could improve adherence and reduce
morbidity associated with P vivax parasitaemia.
World Health Organization guidelines suggest a higher dosing
regimen of primaquine for the tropical, frequent-relapsing strain
of P vivax in East Asia and Oceania (WHO 2015), although the
previous Cochrane Review, Galappaththy 2013, did not find any
trials assessing this. Investigating the evidence base for this is there-
fore important. The 2015 WHO guidelines also suggest an alter-
nate dosing regimen of weekly primaquine, which may be safer
in patients with G6PD deficiency. As the previous Cochrane Re-
view included data from only one trial assessing this, it is useful to
investigate whether there is further evidence to substantiate this
guidance.
In this Cochrane Review, we have excluded comparisons be-
tween blood-stage drug (chloroquine/ACT) with and without pri-
maquine, as the rationale for primaquine use has been sufficiently
demonstrated in a previous Cochrane Review (Galappaththy
2013). Similarly, we have not included comparisons between dif-
ferent blood-stage drugs inwhich the same dose of primaquine was
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used; an update to an existing Cochrane Review, Gogtay 2013, is
in progress and will address this. However, we planned to stratify
our results according to partner drug, as there is increasing evi-
dence that primaquine is metabolized via the cytochrome P450
2D6 (CYP2D6) pathway (Bennett 2013), and efficacy may thus
be affected if the blood-stage antimalarial drug is a CYP2D6 in-
hibitor (Baird 2018). This review excluded comparisons of regi-
mens that do not use the control of the standard or high-standard
regimen of 14 days of primaquine. Also, it did not include com-
parisons of primaquine regimens of 0.25 mg/kg/day for less than
14 days, as Galappaththy 2013 has already assessed these shorter
regimens of the same daily dose.
There is currently a lack of consensus among studies as to what the
minimum time frame for follow-up of relapse in P vivax malaria
should be. TheWHOguidance on clinical trials inmalaria sets out
standard follow-up for blood (or schizontal) stage infection as 28
days after treatment commencement, but has no clear definition
on the follow-up period for radical cure in primaquine studies. It
states that “follow up varies from three months to a year in the lit-
erature, and should be adapted to regional parasite characteristics”
(WHO 2009). In a recent review, John 2012 described relapse of
the tropical frequently relapsing strain of P vivax as typically three
weeks, but this varies according to blood-stage treatment: “three
weeks following quinine therapy” and “six to eight weeks follow-
ing chloroquine” (White 2011). With exposure to primaquine -
even if radical cure is not achieved - relapses may occur at longer
intervals (Sutanto 2013). In the Cochrane Review (Galappaththy
2013), the follow-up period started 30 days after completing pri-
maquine treatment. Relapse is frequently defined as the presence
of P vivax parasites more than 28 to 30 days after the full course of
primaquine in people living in a non-endemic area (Looareesuwan
1997). Due to the varying lengths of treatment and relapse time
in P vivax malaria, 28 days from treatment completion may not
allow true assessment of radical cure. It also makes assessment of
the weekly primaquine regimen difficult, as the follow-up time
should start before the eight-week treatment course has finished.
In this Cochrane Review we planned to assess parasitaemia at 3, 6,
and 12 months’ follow-up, in keeping with WHO guidance. We
intended to describe the length of follow-up across studies, and
then group them intomeaningful lengths of follow-up, depending
on the regimen.
We intended to answer the following questions by comparing the
new regimens to the standard 14-day regimen of primaquine (0.25
mg/kg/day; 15 mg adult dose) or the high-standard 14-day reg-
imen (0.5 mg/kg/day; 30 mg adult dose) recommended for East
Asia/Oceania.
• Is the high-standard 14-day regimen more efficacious and
safer compared to the standard 14-day course in all areas, or only
in areas where it is recommended (East Asia and Oceania)?
• Are shorter, higher-dose regimens (0.5 mg/kg/day for 7
days) as efficacious and safe as the standard 14-day regimen?
• Are weekly dosing regimens (0.75 mg/kg or 45 mg adult
dose/week for 8 weeks) as efficacious and safe as the standard or
high-standard 14-day regimen?
O B J E C T I V E S
To assess the efficacy and safety of alternative primaquine regimens
for radical cure of P vivax malaria compared to the standard or
high-standard 14 days of primaquine (0.25 or 0.5 mg/kg/day), as
well as comparison of these two WHO-recommended regimens.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs). We excluded quasi-RCTs.
Types of participants
Adults and children with confirmed clinical and parasitological
(light microscopy or PCR, or both) diagnosis of P vivax malaria.
We included trials that excluded people withG6PDdeficiency and
trials that included populations that had or had not been screened
for G6PD deficiency. People with mixed malaria infections were
excluded.
Types of interventions
Intervention
Any regimen of either chloroquine or an artemisinin-based com-
bination therapy (ACT) plus primaquine with any of the follow-
ing.
• Daily doses higher than 0.25 mg/kg/day for 14 days.
• Shorter regimens with the same total dose.
• Weekly dosing regimens.
Control
WHO-defined standard regimen of 14 days of primaquine at 0.25
mg/kg/day (15 mg adult dose) in most areas, or high-standard
regimen of 0.5 mg/kg/day (30 mg adult dose) in East Asia and
Oceania, plus either chloroquine or an ACT.
We included comparisons between the two WHO recommended
14 day regimes (0.25mg/kg/day and 0.5mg/kg/day). We included
trials that used chloroquine or ACT as the treatment for blood-
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borne infection, and we planned to stratify by the blood schizon-
ticidal agent.
Types of outcome measures
Primary outcomes
• P vivax parasitaemia (detected by light microscopy or PCR,
or both) at 3, 6, and 12 months’ follow-up. We planned to
describe this as recurrences of P vivax malaria due to the
previously mentioned difficulties in distinguishing between
relapse and re-infection.
Secondary outcomes
• P vivax parasitaemia (detected by light microscopy or PCR,
or both) at one to three months’ follow-up.
Adverse events
• Serious adverse events (fatal, life-threatening, or requiring
hospitalization).
• Adverse events that result in discontinuation of treatment.
• Events known to occur with primaquine (cyanosis,
leucopenia, methaemoglobinaemia, hypertension, cardiac
arrhythmia, abdominal pain, nausea, vomiting, or haemolysis) or
those due to a comparator drug used along with primaquine.
• Anaemia or change in haemoglobin status.
• Other adverse events.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, or
in progress).
Electronic searches
We searched the following databases using the search terms
and strategy described in Appendix 1: the Cochrane Infectious
Diseases Group Specialized Register (17 December 2018); the
Cochrane Central Register of Controlled Trials (CENTRAL,
2018, Issue 12, published in the Cochrane Library); MEDLINE
(PubMed, 1946 to 17 December 2018); Embase (Ovid, 1947
to 17 December 2018); and LILACS (Bireme, 1982 to 17 De-
cember 2018). We also searched the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP;
www.who.int/ictrp/), and ClinicalTrials.gov (clinicaltrials.gov/
ct2/home), for trials in progress, on 17 December 2018, using
“primaquine” and “vivax” as search terms.
Searching other resources
We checked the reference lists of all studies identified by the above
methods for additional potentially relevant studies. We contacted
researchersworking in the field and theWHOfor unpublished and
ongoing trials. We also searched the reference lists and included
studies of the Cochrane Review by Galappaththy 2013.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and abstracts
of the search results to identify potentially eligible trials, coding
the articles as either ’retrieve’ or ’do not retrieve’. We obtained
the full-text reports of potentially eligible trials and assessed them
for inclusion in the review using a predesigned eligibility form
based on the inclusion criteria. Any discrepancies were resolved
through discussion or by consulting a third review author if neces-
sary. Where necessary, we contacted the trial authors for clarifica-
tion of trial methods. We listed the excluded trials and the reasons
for their exclusion in a ’Characteristics of excluded studies’ table.
Where there were multiple reports relating to the same trial, we
planned to include all reports and collate data. We detailed the
trial selection process in a PRISMA diagram.
Data extraction and management
Two review authors independently extracted data from the in-
cluded trials using a data extraction form designed specifically for
this review, in keeping with Cochrane guidance (Higgins 2011).
For each included trial we extracted a minimum of the following
data where available.
• Study design.
• Endemicity/population demographics.
• G6PD status of participants (known/unknown).
• CYP2D6 status (if available).
• Blood-stage antimalarial drug choice.
• Dose/duration/timing of treatment arms.
• Supervised or non-supervised therapy.
• Duration of follow-up.
• Adverse events.
• Reported outcomes.
Any differences in data extractionwere resolved through discussion
or by consulting a third review author if necessary. We entered the
extracted data into Review Manager 5 (RevMan 2014). Where
necessary, we contacted the authors of primary trials regarding
missing data or methodological details of the trial. We noted any
limitations in the included studies.
We grouped comparisons as illustrated in Table 1.
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Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included trial using the Cochrane ’Risk of bias’ assessment tool,
discussing any differences of opinion. In the case of missing or
unclear information, we contacted the trial authors for clarifica-
tion. We summarized the results in the ’Risk of bias’ tables in the
’Characteristics of included studies’ tables (Higgins 2011).
Measures of treatment effect
For dichotomous data, we compared interventions using risk ratios
(RRs) to measure treatment effect. Where trial authors presented
data as odds ratios, we recalculated the effect.We defined statistical
significance as P < 0.05 and calculated 95% confidence intervals
(CIs) for all results. For comparable trials, we performed meta-
analyses if there were sufficient data.
Unit of analysis issues
We split trials that included more than two comparison groups
and analysed them as individual pair-wise comparisons. If there
was a shared control group, we split the control group so that
participants were only counted once in the overall meta-analysis.
Dealing with missing data
We analysedmissing data using available-case analysis if we judged
the trial to be at low risk of bias for incomplete outcome data.
We attempted to contact trial authors to obtain missing or un-
clear data. If the missing data rendered the result uninterpretable,
we excluded the data from meta-analyses and clearly stated the
reason for exclusion. If the missing data meant that results were
interpretable but likely to be at high risk of bias, we used impu-
tation methods to investigate the impact of the missing data. We
analysed extracted data on an intention-to-treat basis where there
were no missing data.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs. We also applied
the Chi² test as a statistical test for the presence of heterogeneity,
with a P value of 0.10 used to indicate statistical significance, and
we computed the I² statistic to quantify the percentage of the
variability in effect estimates that was due to heterogeneity rather
than sampling error (chance). We investigated possible causes of
heterogeneity by subgroup analysis. If substantive heterogeneity
persisted, defined as an I² statistic value of greater than 50%, we
used a random-effects meta-analysis.
Assessment of reporting biases
We planned to examine the likelihood of reporting bias using fun-
nel plots, however the number of included trials was insufficient
to permit this.
Data synthesis
We analysed the data using Review Manager 5 (RevMan 2014).
We assessed the certainty of the evidence for each outcome mea-
sure using the GRADE approach, and we constructed ’Summary
of findings’ tables using GRADEpro GDT (GRADEpro GDT
2015). We stratified results according to blood-stage partner drug
(if different blood-stage antimalarials were used, which only oc-
curred for one comparison). Length of follow-up varied with reg-
imens and between studies. We described regimens and follow-
up periods and defined sensible groupings for follow-up. We also
performed subgroup analyses according to geographical region/
endemicity and directly observed therapy (DOT) or non-DOT.
We stratified results by length of follow-up. We had planned to
perform a subgroup analysis according to CYP2D6 status, how-
ever data were insufficient to permit this.
Subgroup analysis and investigation of heterogeneity
We grouped the analysis by drug regimen. We described the inter-
ventions and outcomes in all included trials. We conducted an in-
ventory of length of follow-up against each drug regimen and then
grouped P vivax parasitaemia recurrence by appropriate groupings
for length of follow-up.
Sensitivity analysis
Weplanned to assess the risk of bias of studies that contributed data
to the meta-analyses for the prespecified outcomes with sensitivity
analyses against concealment of allocation.
R E S U L T S
Description of studies
Results of the search
Our database search, conducted up to 17 December 2018, identi-
fied 251 studies (after removal of 3 duplicates). We excluded 214
articles during abstract screening, and selected 37 studies for full-
text review. We excluded 25 studies with reasons provided; iden-
tified two trials as ongoing; and included 10 studies in the review.
The search results are presented in a PRISMA diagram in Figure
2.
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Figure 2. Study flow diagram.
Included studies
Although 10 studies (of 10 trials) met our inclusion criteria, one
study was deemed ineligible for data extraction and analysis. There
were only partially available results available in a conference ab-
stract for Chu 2016 THA,meaning that we could not assess risk of
bias or analyse results. We contacted the author for the full results
but this was declined pending future publication. We included
nine studies (of nine trials) in our quantitative analysis.
Four trials were conducted in South America: one in Colombia
(Carmona-Fonseca 2009 COL), one inBrazil (Abdon 2001 BRA),
and two in Peru (Solari-Soto 2002 PER; Durand 2014 PER). Five
trials were conducted in Asia: one in Pakistan (Leslie 2008 PAK),
one in Thailand (Bunnag 1994 THA), and three in India (Rajgor
2014 IND; Pareek 2015 IND; Saravu 2018 IND). All nine trials
included data for adults, and four trials included children under
the age of 10 years (Solari-Soto 2002 PER; Leslie 2008 PAK;
Carmona-Fonseca 2009 COL; Durand 2014 PER). No trials had
information on children under one year old.
Seven trials excluded pregnant women, and two trials did not spec-
ify whether or not pregnant women were included (Bunnag 1994
THA; Solari-Soto 2002 PER). Six trials specified that lactating
women were excluded, while the remaining three trials did not
provide details regarding this (Bunnag 1994 THA; Solari-Soto
2002 PER; Carmona-Fonseca 2009 COL). Only one trial in-
cluded people with G6PD deficiency (Leslie 2008 PAK). Six tri-
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als excluded people with G6PD deficiency (Bunnag 1994 THA;
Carmona-Fonseca 2009 COL; Durand 2014 PER; Rajgor 2014
IND; Pareek 2015 IND; Saravu 2018 IND), and two trials did
not specify whether or not people with G6PD deficiency were in-
cluded (Abdon 2001 BRA; Solari-Soto 2002 PER). All of the trials
used microscopy for diagnosis of parasitaemia. Four trials carried
out PCR genotyping of vivax parasitaemia as well (Durand 2014
PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018 IND).
Two trials used different doses or regimens of chloroquine within
trial arms, but as both confirmed that parasitaemia had resolved
following treatment, we still included them in the review (see
Characteristics of included studies) (Bunnag 1994 THA; Abdon
2001 BRA). None of the included trials described the CYP2D6
status of participants.
Excluded studies
We excluded 25 studies during full-text screening; see details in
Characteristics of excluded studies.
Risk of bias in included studies
A summary of the ’Risk of bias’ assessments is presented in Figure
3. Full details are shown in the Characteristics of included studies
tables.
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Figure 3. ‘Risk of bias’ summary: review authors’ judgements about each ‘Risk of bias’ item for each
included study.
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Allocation
Four trials described adequate methods of treatment randomiza-
tion and were judged to be at low risk of selection bias (Durand
2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018
IND). We assessed one trial as being at high risk of bias as it
used two different methods of randomization depending on loca-
tion, using house numbers or sequential patient numbers (Leslie
2008 PAK). Four trials did not detail the randomization process
(Bunnag 1994 THA; Abdon 2001 BRA; Solari-Soto 2002 PER;
Carmona-Fonseca 2009 COL).
Two trials used sealed envelopes to conceal allocation and so were
assessed as being at low risk of bias (Durand 2014 PER; Pareek
2015 IND). We assessed two trials with no concealment of treat-
ment allocation as at high risk of bias (Leslie 2008 PAK; Rajgor
2014 IND), while five trials provided no information on whether
or not allocation concealment was used(Bunnag 1994 THA;
Abdon 2001 BRA; Solari-Soto 2002 PER; Carmona-Fonseca
2009 COL; Saravu 2018 IND).
Blinding
Seven trials were open-label and were assessed as at high risk of
performance bias (Abdon 2001 BRA; Solari-Soto 2002 PER;
Leslie 2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014
PER; Rajgor 2014 IND; Saravu 2018 IND); two of these trials
reported blinding of the microscopists who analysed the blood
work (Leslie 2008 PAK; Rajgor 2014 IND). Two trials reported
blinding of participants and personnel and were classified as being
at low risk of bias (Bunnag 1994 THA; Pareek 2015 IND).
Incomplete outcome data
Five trials had low rates of attrition with losses accounted for and
so were judged as at low risk of attrition bias (Abdon 2001 BRA;
Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Durand
2014 PER; Pareek 2015 IND). We assessed four trials as at high
risk of attrition bias. Bunnag 1994 THA had unexplained, signif-
icant loss to follow-up (more than three-quarters of participants
by the end of the trial), making the results uninterpretable. Leslie
2008 PAK had a higher loss to follow-up in the intervention group
compared to the control group (6% loss versus 1% loss). Rajgor
2014 IND had a high percentage of missing results at six months.
Saravu 2018 IND had a high percentage of loss to follow-up in
both arms by six months.
Selective reporting
We judged four trials to have adequately reported on either pre-
specified or expected outcomes (Abdon 2001 BRA; Leslie 2008
PAK; Durand 2014 PER; Saravu 2018 IND). Risk of report-
ing bias was unclear for five trials as no protocols were available
(Bunnag 1994 THA; Solari-Soto 2002 PER; Carmona-Fonseca
2009 COL; Rajgor 2014 IND; Chu 2016 THA). We assessed
Pareek 2015 IND as being at high risk of reporting bias because
compliance was added as an outcome, primaquine levels were not
reported as planned, and PCR results were not well-detailed.
Other potential sources of bias
We judgedPareek 2015 INDtobe at high risk of other bias as it was
funded by the drug company that manufactured the primaquine
preparations, and the authors were employees of the company. We
assessed six trials as at low risk of other bias (Solari-Soto 2002
PER; Leslie 2008 PAK; Carmona-Fonseca 2009 COL; Durand
2014 PER; Rajgor 2014 IND; Saravu 2018 IND). We assessed
two trials for which funding was not detailed as at unclear risk of
other bias (Bunnag 1994 THA; Abdon 2001 BRA).
Effects of interventions
See: Summary of findings for the main comparison ‘Summary
of findings’ (main comparison); Summary of findings 2
‘Summary of findings’ table 2; Summary of findings 3 ‘Summary
of findings’ table 3
High-standard 14-day regimen versus standard 14-day
regimen
The WHO recommends higher doses of primaquine (0.5 mg/kg/
day) for 14 days in East Asia andOceania.We intended to examine
whether this high-standard regimen was more efficacious in areas
where it is currently recommended (because of assumed resistance
- East Asia, Oceania) as well as in all other areas where resistance
is not thought to occur.
Two trials compared the high-standard 14-day course with the
standard (0.25 mg/kg/day) 14-day course, both carried out in
adults in India (Rajgor 2014 IND; Saravu 2018 IND). Both tri-
als excluded pregnant/lactating and G6PD-deficient patients. In
Rajgor 2014 IND, participants were treated with chloroquine,
with the primaquine regimen (which was supervised) given after
completion of the chloroquine course. In Saravu 2018 IND, par-
ticipants were treated with either chloroquine or an ACT (arte-
sunate with doxycycline or artemether-lumefantrine), and (unsu-
pervised) primaquine was given after completion of the blood-
stage treatment. We planned to stratify results according to blood-
stage treatment; however, Saravu 2018 IND combined the results
for both blood-stage treatments, so we were unable to separate re-
sults according to partner drug. Only the blood-stage drugs given
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to participants who had recurrences were described. For this rea-
son, results from the two studies are not combined and are pre-
sented separately.
Efficacy
In Rajgor 2014 IND, 21 participants out of 317 in the high-stan-
dard 14-day group had a recurrence of vivax malaria compared
with 26 out of 322 in the standard 14-day group at 6 months’
follow-up, giving an 18% reduction in recurrence of parasitaemia
in the high-standard group (risk ratio (RR) 0.82, 95% confidence
intervals (CI) 0.47 to 1.43; 639 participants; very low-certainty
evidence; Analysis 1.1). Vivax malaria recurrences were also inves-
tigated by PCR to determine whether they were true relapses or
new infections. After this adjustment, results showed an 83% in-
crease in vivax malaria cases in the high-standard group (RR 1.83,
95% CI 0.62 to 5.40; Analysis 1.2).
Rajgor 2014 IND was at high risk of bias for allocation conceal-
ment. However, as we chose not to combine the data with Saravu
2018 IND for this analysis, a sensitivity analysis could not be done.
In Saravu 2018 IND, 2 out of 18 participants in the high-standard
14-day group had a recurrence of P vivax malaria compared to 2
out of 20 in the standard 14-day group at 6 months’ follow-up
(RR 1.11, 95% CI 0.17 to 7.09; Analysis 1.1). Both of the recur-
rences in the high-standard 14-day group were given chloroquine.
Of the recurrences in the standard 14-day group, one participant
received chloroquine and one participant received artesunate and
doxycycline. Polymerase chain reaction genotyping suggested that
all four participants had true relapses of infection.
It should be noted that because Saravu 2018 INDwas a small pilot
trial, if we had not stratified according to blood-stage treatment,
results would have been largely the same as for Rajgor 2014 IND
alone.
Adverse effects
In Rajgor 2014 IND there were no serious adverse events were re-
ported in either study arm (778 participants). In the high-standard
14-day group, 8 out of 380 participants discontinued treatment
due to adverse events, compared to 2 out of 398 in the standard
14-day group (RR 4.19, 95% CI 0.90 to 19.60; 778 participants;
very low-certainty evidence; Analysis 1.4). In the high-standard
arm, 13 out of 380 participants experienced adverse events known
to occur with primaquine, compared to 5 out of 398 in the stan-
dard arm (RR 2.72, 95% CI 0.98 to 7.57; 778 participants; very
low-certainty evidence; Analysis 1.5). In the high-standard arm, 4
out of 380 participants experienced adverse events known to occur
with the blood-stage antimalarial chloroquine, compared to 0 out
of 398 in the standard group (RR 9.43, 95% CI 0.51 to 174.47;
778 participants; very low-certainty evidence; Analysis 1.6). This
could suggest a trend towards a higher occurrence of adverse events
in the high-standard 14-day regimen.
No significant adverse events were noted in either group in Saravu
2018 IND.
0.5 mg/kg/day for 7 days versus standard 14-day
regimen
This comparison aimed to investigatewhether shorter, higher-dose
regimens of primaquine over 7 days are as efficacious as standard
treatment over 14 days to determine whether the total dose rather
than the length of treatment is an important factor (total dose 210
mg).
Five trials in India and South America compared 0.5 mg/kg/day
of primaquine for 7 days versus the standard (0.25 mg/kg/day)
14-day regimen (same total dose 210 mg) (Abdon 2001 BRA;
Solari-Soto 2002 PER; Durand 2014 PER; Rajgor 2014 IND;
Pareek 2015 IND). Pareek 2015 IND used a sustained-release
preparation of primaquine in two of the study arms (0.5 mg/kg/
day sustained release and 0.25 mg/kg/day sustained release) and
standard primaquine at 0.25mg/kg/day in a third arm. We in-
cluded the 0.5 mg/kg/day sustained release in the analysis and
combined the results with the standard preparation at the same
dose used for the other trials, but used only the standard-prepa-
ration group of 0.25 mg/kg/day in the study as the control group
and did not include the arm of 0.25mg/kg/day sustained release
preparation.
Three trials excluded people with G6PD deficiency, while two
trials did not provide this information (Bunnag 1994 THA;
Solari-Soto 2002 PER). All but one trial excluded women who
were pregnant or lactating (Solari-Soto 2002 PER did not provide
details). Participants were a mixture of adults and children over
one year old. All trials used microscopy for diagnosis, and only
Pareek 2015 IND did not use supervised treatment. Two trials
gave chloroquine and primaquine courses simultaneously (Abdon
2001 BRA; Durand 2014 PER), while the other three trials ad-
ministered primaquine following the chloroquine course. No tri-
als stratified by age, so results were combined.
Efficacy
Therewasminimal difference in the number ofmalaria recurrences
between groups at 6 to 7 months’ follow-up (RR 0.96, 95% CI
0.66 to 1.39; 1211 participants; low-certainty evidence; Analysis
2.1). One trial only followed participants for two months (Solari-
Soto 2002 PER), and so was not part of the main analysis.
We had planned to perform a sensitivity analysis based on risk
of bias for allocation concealment (which would have involved
removing Rajgor 2014 IND from the meta-analysis), but we de-
cided that as the remaining trials were all at high risk of bias for
blinding and thus quality was generally low, we would not con-
duct a sensitivity analysis but address these issues in our GRADE
assessment.
Two trials PCR-adjusted their results to differentiate between re-
lapses and new infections at 6 to 7 months’ follow-up. In Durand
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2014 PER, PCR-adjusted results showed a 31% reduction in re-
currence (24% reduction with light microscopy) with the regimen
of 0.5 mg/kg/day for 7 days compared with the standard 14-day
course, while in Rajgor 2014 IND, PCR-adjusted results showed
a 159% increase in recurrence (25% increase in recurrence with
light microscopy) with the regimen of 0.5 mg/kg/day for 7 days
compared to the standard 14-day regimen (Analysis 2.2). We de-
cided that these results could not be combined in a meta-analysis,
as PCR techniques can differ, and there were high levels of het-
erogeneity.
We performed a subgroup analysis according to geographic region
(Analysis 2.3). For trials in South America, the regimen of 0.5 mg/
kg/day for 7 days led to a 30% reduction in P vivax recurrences
compared to a 19% increase in recurrences for trials in Asia, al-
though confidence intervals were wide and included no effect for
both subgroups (South America: RR 0.70, 95% CI 0.39 to 1.26;
Asia: RR 1.19, 95% CI 0.73 to 1.94). Only one trial did not use
directly observed therapy (DOT) (Pareek 2015 IND). Subgroup
analysis (Analysis 2.4) showed that with DOT there was minimal
difference in recurrences at 6 to 7 months between treatment reg-
imens (RR 0.98, 95% CI 0.67 to 1.43) compared to a reduction
of about half of recurrences with the regimen of 0.5 mg/kg/day
for 7 days when treatment was not supervised (RR 0.48, 95% CI
0.04 to 5.20).
Adverse effects
No serious adverse events were reported in either group (1427
participants). The number of participants experiencing adverse
events leading to discontinuation of treatment was similar in both
groups (RR1.04, 95%CI0.15 to 7.38; 1154 participants; Analysis
2.6), as were adverse events known to occur with primaquine (RR
1.06, 95% CI 0.64 to 1.76; 1154 participants; Analysis 2.7). One
trial reported on change in haemoglobin status (Pareek 2015
IND), with 1 participant out of 120 in the group receiving 0.5mg/
kg/day for 7 days becoming anaemic, versus no participants out of
120 in the standard 14-day regimen group (RR 3.0, 95% CI 0.51
to 174.01; 240 participants; very low-certainty evidence; Analysis
2.8). Only one study reported on adverse events known to occur
with chloroquine (Rajgor 2014 IND), with more occurring in the
group receiving 0.5 mg/kg/day for 7 days than the standard 14-
day group (RR 9.40, 95% CI 0.51 to 174.01; 779 participants;
very low-certainty evidence; Analysis 2.9).
0.75 mg/kg primaquine/week for 8 weeks versus high-
standard 14-day regimen
This comparison aimed to investigate whether a higher once-
weekly dosing regimen, which may be more beneficial for people
with G6PD deficiency, was as efficacious as the high-standard 14-
day regimen.
One trial compared weekly 0.75 mg/kg primaquine (45 mg adult
dose) for 8 weeks with the high-standard 14-day regimen (0.5
mg/kg/day) (Leslie 2008 PAK). G6PD-deficient participants were
not randomized but were included in the weekly group, although
there only was one G6PD-deficient person included. Pregnant
and lactating women were excluded. Treatment was supervised. It
was not specified whether chloroquine and primaquine were given
concurrently.
Efficacy
Recurrences were more common in the weekly group at 8 months’
follow-up (RR 7.0, 95% CI 0.38 to 127.32; 126 participants;
Analysis 3.1). Recurrences remained more common in the weekly
group at 11 months’ follow-up (RR 3.18, 95% CI 0.37 to 27.6;
122 participants; Analysis 3.1). Leslie 2008 PAK was at high risk
of bias for allocation concealment, but a sensitivity analysis could
not be done as it was the only trial found for this comparison.
Adverse effects
No serious adverse events were reported in either study arm
(Analysis 3.2). No participants had anaemia defined as haemoglo-
bin less than 7 g/dL (Analysis 3.3).
Other regimens
0.375 mg/kg/day for 14 days versus standard 14-day regimen
Bunnag 1994 THA compared 0.375 mg/kg/day (adult dose 22.5
mg) primaquine daily for 14 days with the standard regimen of
0.25 mg/kg/day for 14 days. There was a high loss to follow-up,
with 167 participants enrolled and only 38 completing 18months’
follow-up, although the loss was equal in both groups at the end
of follow-up. At 6 months’ follow-up there were no episodes of
P vivax in the experimental group (0/40) and two recurrences
in the standard-regimen group (2/33) (RR 0.17, 95% CI 0.01
to 3.34; 73 participants; Analysis 4.1), although only about half
of enrolled participants were followed up at this time point. No
further recurrences were described in either group up to the end
of follow-up at 18 months, but as described, the high level of
unexplained dropout makes interpretation difficult.
No formal assessment of adverse events was reported, but it ismen-
tioned in the study narrative that there was no drop in haematocrit
or haemoglobinuria in either group.
1.17 mg/kg/day for 3 days versus standard 14-day regimen
One trial delivered the total dose of primaquine (1.17 mg/kg/day
or 70 mg adult dose, total dose 210 mg) over 3 days versus the
standard (0.25 mg/kg/day) 14-day regimen (Carmona-Fonseca
2009 COL). Recurrences of P vivax malaria were more common
in the group receiving 1.17 mg/kg/day for 3 days than in the
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standard 14-day group at 4 months’ follow-up (RR 3.88, 95% CI
2.11 to 7.11; 129 participants; Analysis 5.1).
Adverse events were not reported, although it was noted that there
were no serious adverse events from co-administering primaquine
and chloroquine.
1 mg/kg/day for 7 days versus high-standard 14-day regimen
This comparison aimed to investigate whether shorter, higher
doses of primaquine over 7 days are as effective as the high-stan-
dard 14-day regimen to determine whether the total dose rather
than the length of treatment is the important factor for East Asia
and Oceania regimen (total dose 420 mg primaquine). Only one
included trial compared 1 mg/kg/day (adult dose 60 mg) of pri-
maquine for 7 days with the high-standard 14-day course (0.5mg/
kg/day) (Chu 2016 THA), administering the regimen with either
chloroquine or an ACT (4 arms). Results are still awaited, but a
conference report of the trial reports that out of 680 participants
there was no difference between the two regimens. No further de-
tails are currently available.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
High-standard 14-day regimen versus standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with conf irmed clinical and parasitological P vivax malaria
Setting: India
Intervention: high-standard 14-day course of primaquine (0.5 mg/ kg/ day, adult dose 30 mg)
Comparison: standard 14-day course of primaquine (0.25 mg/ kg/ day, adult dose 15 mg)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard 14-
day course primaquine
Risk with high-stan-
dard 14-day course pri-
maquine
Recurrence of P vivax
parasitaemia
follow-up: range 6
months to 7 months
Blood-stage treatment:
chloroquine
81 per 1000 66 per 1000
(34 to 116)
RR 0.82
(0.47 to 1.43)
639
(1 RCT)
⊕©©©
VERY LOWa,b,c
due to indirectness, risk
of bias, and imprecision
We do not know if
there is any dif fer-
ence in P vivax recur-
rences between high-
standard or standard
14-day courses of pri-
maquine given with
chloroquine
Recurrence of P vivax
parasitaemia
follow-up: range 6
months
Blood-stage treatment:
chloroquine or an ACT
100 per 1000 111 per 1000
(17 to 709)
RR 1.11 (0.17 to 7.09) 38
(1 RCT)
⊕©©©
VERY LOWd,e,f
due to indirectness, risk
of bias, and imprecision
We do not know if
there is any dif fer-
ence in P vivax recur-
rences between high-
standard or standard
14-day courses of pri-
maquine given with
chloroquine or an ACT
Serious adverse ef fects 0 per 1000 0 per 1000
(0 to 0)
Not est imable 816
(2 RCTs)
- No events reported.
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Adverse events that re-
sult in the discont inua-
t ion of treatment
5 per 1000 21 per 1000
(5 to 98)
RR 4.19
(0.90 to 19.60)
778
(1 RCT)
⊕©©©
VERY LOWa,b,d,g
due to indirectness, risk
of bias, and imprecision
We do not know if there
is any dif ference in ad-
verse events result ing
in treatment discont in-
uat ion between high-
standard or standard
14-day courses of pri-
maquine
Adverse ef fects known
to occur with pri-
maquine
13 per 1000 34 per 1000
(12 to 95)
RR 2.72
(0.98 to 7.57)
778
(1 RCT)
⊕©©©
VERY LOWa,b,h
due to indirectness, risk
of bias, and imprecision
We do not know if
there is any dif fer-
ence in adverse events
known to occur with pri-
maquine between high-
standard or standard
14-day courses of pri-
maquine
Adverse events known
to occur with chloro-
quine
0 per 1000 0 per 1000
(0 to 0)
RR 9.43
(0.51 to 174.47)
778
(1 RCT)
⊕©©©
VERY LOWa,b,h
due to indirectness, risk
of bias, and imprecision
We do not know if
there is any dif ference
in adverse events asso-
ciated with chloroquine
between the 2 treat-
ment groups
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: ACT: artemisinin-based combinat ion therapy; CI: conf idence interval; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once for indirectness: only one trial conducted in India in G6PD-normal adults (Rajgor 2014 IND).
2
1
P
rim
a
q
u
in
e
a
t
a
lte
rn
a
tiv
e
d
o
sin
g
sc
h
e
d
u
le
s
fo
r
p
re
v
e
n
tin
g
re
la
p
se
in
p
e
o
p
le
w
ith
P
la
sm
od
iu
m
viva
x
m
a
la
ria
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
bDowngraded once for risk of bias: open-label - no allocat ion concealment, risk of select ion bias; risk of attrit ion bias - high
percentage not complet ing six months’ follow-up with minimal explanat ion.
cDowngraded once for imprecision: wide CIs - range of 58% reduct ion in malaria recurrences at 6 months with high-standard
14-day course of primaquine to 43% increase in number of malaria recurrences.
dDowngraded once for indirectness: only one trial conducted in India in G6PD-normal adults (Saravu 2018 IND).
eDowngraded once for risk of bias: no blinding, high rate of loss to follow-up.
fDowngraded once for imprecision: wide CIs - range of 83% reduct ion in malaria recurrence to 609% increase in malaria
recurrences with the high-standard 14-day regimen.
gDowngraded once for imprecision: wide CIs 0.9 to 19.6 - range of 10% reduct ion in adverse events with high-standard 14-day
course to 186% increase in adverse events.
hDowngraded once for imprecision: wide CIs.
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0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with conf irmed clinical and parasitological P vivax malaria
Setting: Pakistan
Intervention: 0.75 mg/ kg primaquine/ week for 8 weeks (adult dose 45 mg)
Comparison: high-standard 14-day course primaquine (0.5 mg/ kg/ day, adult dose 30 mg)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with high-stan-
dard 14-day course pri-
maquine
Risk with once-weekly
0.75 mg/kg primaquine
for 8 weeks
Recurrence of P vivax
malaria
Follow-up: 8 months
0 per 1000 0 per 1000
(0 to 0)
RR 7.00
(0.38 to 127.32)
126
(1 RCT)
⊕©©©
VERY LOWa,b,c
due to risk of bias, in-
directness, and impre-
cision
We
do not know if weekly
primaquine reduces the
risk of malaria recur-
rences when compared
to the high-standard 14-
day course
Recurrence of P vivax
malaria
Follow-up: 11 months
19 per 1000 59 per 1000
(7 to 511)
RR 3.18
(0.37 to 27.60)
122
(1 RCT)
⊕©©©
VERY LOWa,b,d
due to risk of bias, in-
directness, and impre-
cision
We
do not know if weekly
primaquine reduces the
risk of malaria recur-
rences when compared
to the high-standard 14-
day course
Serious adverse ef fects 0 per 1000 0 per 1000
(0 to 0)
Not est imable 129
(1 RCT)
- No events reported.
Anaemia (haemoglobin
< 7 g/ dL)
0 per 1000 0 per 1000
(0 to 0)
Not est imable 129
(1 RCT)
- No events reported.
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*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RCT: randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by 1 for risk of bias: Leslie 2008 PAK was at high risk of bias for randomizat ion process, allocat ion concealment,
and incomplete outcome data.
bDowngraded by 1 for indirectness: only one study conducted in Pakistan, only one G6PD-def icient adult included in one trial
(in weekly arm).
cDowngraded by 2 for serious imprecision: few events, very wide CIs.
dDowngraded by 2 for serious imprecision: few events, very wide CIs.
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D I S C U S S I O N
Summary of main results
High-standard 14-day regimen versus standard 14-day
regimen
See Summary of findings 2
We included 2 RCTs that compared 0.5 mg/kg/day primaquine
(daily adult dose 30 mg) for 14 days with 0.25 mg/kg/day (daily
adult dose 15 mg) for 14 days, both conducted in India. People
with G6PD deficiency and pregnant or lactating women were
excluded. One trial did not account for whether participants were
given chloroquine or an ACT for blood-stage treatment. We do
not know if there is any difference in P vivax recurrences at 6
months with the high-standard 14-day course compared to the
standard 14-day course when given with chloroquine (very low-
certainty evidence). We do not know if there is any difference
in P vivax relapses at 6 months with the high-standard 14-day
course compared to the standard 14-day course when given with
chloroquine or an ACT (very low-certainty evidence).
No serious events were reported in either trial. We do not know
whether there is a difference in adverse events between the high-
standard 14-day course and the standard 14-day course (very low-
certainty evidence).
0.5 mg/kg/day for 7 days versus standard 14-day
regimen
See Summary of findings for the main comparison
We included 5 RCTs that compared 0.5 mg/kg/day (adult dose
30 mg) primaquine for 7 days with the standard 14-day regimen
(0.25 mg/kg/day). There may be little or no difference in P vivax
recurrences at 6 to 7 months when using the same total dose (210
mg) over 7 days as compared to 14 days (low-certainty evidence).
No serious adverse events were reported. There may be little or no
difference in the number of adverse events known to occur with
primaquine when using the shorter regimen as compared to the
longer regimen (low-certainty evidence).
We do not know whether there is any difference in the frequency
of anaemia or discontinuation of treatment between groups (very
low-certainty evidence). Three trials excluded people with G6PD
deficiency, and two did not provide this information, so we do not
know the effect of the higher daily dose regimen in this group.
Pregnant and lactating women were either excluded or this infor-
mation was not provided.
0.75 mg/kg primaquine/week for 8 weeks versus high-
standard 14-day regimen
See Summary of findings 3
We included 1 RCT that compared 0.75 mg/kg (daily adult dose
45 mg) weekly primaquine for 8 weeks with the high-standard 14-
day regimen (0.5 mg/kg/day, daily adult dose 30 mg). G6PD-de-
ficient participants were not randomized but were included in the
weekly primaquine group. Only one G6PD-deficient participant
was detected during the trial andwas included in the weekly group.
We do not know whether weekly primaquine reduces recurrence
of P vivax compared to the high-standard 14-day regimen at 8 to
11 months’ follow-up (very low-certainty evidence).
No serious adverse events and no episodes of anaemia were re-
ported.
Some other included trials evaluated alternative regimens and
doses of primaquine, but these regimens have not been widely
used, and the evidence available from stand-alone trials was of very
low certainty.
Overall completeness and applicability of
evidence
We initially thought we could evaluate whether the high-standard
14-day regimen (0.5 mg/kg/day) was more effective in all areas
rather than just areas where recommended by the WHO due to
reported resistance or strain differences (East Asia and Oceania)
(WHO 2015). However, we only found two trials that compared
the high standard 14-day regimen to the standard 14-day regimen,
both of which were conducted in India. A recent retrospective case
review in French Guiana (also an area where the high-standard
regimen is not currently recommended) found that recurrences
were similar in both standard and high-standard 14-day regimens
(Valdes 2018). We did not find any RCTs that evaluated whether
the high-standard 14-day regimen was more effective compared to
the standard 14-day regimen for the tropical, frequently relapsing
strain of P vivax in East Asia and Oceania, so we are unable to
comment on its efficacy.
A difficulty encountered in including and comparing studies was
the variation in dosing and length of follow-up in studies.
In general, there were few well-conducted RCTs that used an evi-
dence-based standard primaquine regimen (15 mg/kg/day for 14
days) as a comparator. Some trials used the high-standard 0.5
mg/kg/day for 14 days regimen as a comparator, which is recom-
mended by the WHO in East Asia and Oceania, which is why we
included these trials. However, there is limited clear evidence in
this review for the increased high-standard 14-day regimen. We
found two randomized clinical trials that compared its efficacy
to the standard regimen, both of which were conducted in India
(Rajgor 2014 IND; Saravu 2018 IND), where the regimen is not
recommended.
We also found that trials continue to be conducted where placebo
is used instead of an alternative primaquine regimen, which is
contrary to the evidence available demonstrating its superiority for
reducing recurrences (Galappaththy 2013). This may be because
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there is continued reluctance to use primaquine in some national
programmes.
We excluded studies where individuals had mixed malaria infec-
tions so as to assess the efficacy of treatment on P vivax malaria
alone. Areas endemic for P vivax malaria may also be co-endemic
for P falciparum or Plasmodium ovale infection, or both. However,
it should be noted that as part of our screening process we did not
identify any studies where participants with mixed malaria were
included, so we do not think that narrowing our search criteria
impacted the directness of our results.
Although the evidence is currently of low certainty, it does appear
that using 0.5 mg/kg/day with the same total dose (210 mg) over
7 days may be non-inferior to the regimen of 0.25 mg/kg/day for
14 days. It may be that these shorter regimens promote course
completion. Although no serious adverse events were reported due
to few reported events for any other adverse effects, it is difficult
to draw conclusions as to whether there may be increased adverse
events for this higher dosing until more data are available. This
higher-dose regimen was not tested in G6PD-deficient patients in
any of the RCTs meeting our inclusion criteria. This remains a
concern in settings where testing is not available.
There was a general lack of detailed safety data for trials, which
is interesting given that safety is a particular concern with pri-
maquine use. Only one included RCT investigated the weekly
primaquine regimen that is currently recommended by WHO for
G6PD-deficient individuals, and only one G6PD-deficient par-
ticipant was actually included in the treatment group.
Certainty of the evidence
The overall certainty of evidence for all of the outcomes was either
low or very low. All results were downgraded for imprecision due
to wide CIs for all of the meta-analyses performed.
The efficacy comparison for the high-standard 14-day regimen
versus the standard 14-day regimen was also downgraded for indi-
rectness. Results were based on two trials in adults in India (Rajgor
2014 IND; Saravu 2018 IND). Rajgor 2014 IND was at risk of
bias as there was no allocation concealment and unexplained loss
to follow-up; this study also contributed most to the meta-analysis
for the comparison of 0.5 mg/kg/day for 7 days versus standard
14-day regimen, so this study was also downgraded. Saravu 2018
IND was a small pilot study where participants were given either
chloroquine or an ACT for the blood stage, and which blood-stage
treatment they were given was not stated. Saravu 2018 IND was
downgraded for imprecision, indirectness, and risk of bias (not
blinded and high rate of loss to follow-up).
Wedowngraded the comparisonof 0.75mg/kgweekly primaquine
versus high-standard 14-day regimen for indirectness as it was
based on just one study conducted in Pakistan (Leslie 2008 PAK),
with only one G6PD-deficient patient participating. Leslie 2008
PAK was at risk of bias due to the randomization process used,
lack of allocation concealment, and incomplete outcome data.
We downgraded efficacy outcomes for this comparison for serious
imprecision due to few events and very wide CIs.
Potential biases in the review process
The strictness of our inclusion criteria to not include trials where
the total dose was less than the total dose of the standard regimen
and the necessity of having the comparison arm be one of the
WHO-recommended regimens may have meant that some rele-
vant comparisons were excluded.
We changed the protocol to include the high-standard 14-day
regimen that WHO recommends in East Asia and Oceania as a
control regimen, as we realized that some trials had used this as
the comparator, and we felt that these comparisons were useful.
However, this may have introduced bias, as per our results the
evidence base for RCTs showing the efficacy of this regimen is
limited.
The difficulty in determining between relapse and re-infection
with P vivax remains a recognized challenge for assessing the effi-
cacy of drugs for radical cure.
Agreements and disagreements with other
studies or reviews
Our findings that 210 mg over 7 days may be as efficacious as
210 mg over 14 days are similar to the findings of other system-
atic reviews that examined both randomized and non-random-
ized studies (Carmona-Fonseca 2015; Zuluaga-Idarraga 2015).
Other reviews also commented on the difficulty of comparing re-
sults due to the varying treatment regimens and length of fol-
low-up used in clinical trials (John 2012; Carmona-Fonseca 2015;
Zuluaga-Idarraga 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although limited data were available, no difference was detected
for efficacy between the regimen of 0.5 mg/kg/day for 7 days and
the standard (0.25 mg/kg/day) 14-day regimen in G6PD-normal
patients.
No serious adverse events were reported in G6PD-normal patients
taking 0.5 mg/kg/day of primaquine.
Implications for research
Further high-quality randomized controlled trials are needed with
more standardized comparison regimens and length of follow-
up, in particular investigating the use of the high-standard 14-
day regimen, same total dose over 7 days, and weekly regimens in
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G6PD-deficient patients. Trials such as IMPROVwill help resolve
some of the uncertainties.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdon 2001 BRA
Methods RCT
July 1994 to June 1995
Participants 120 participants enrolled.
Inclusion criteria:
• Confirmed parasitological diagnosis for P vivax malaria.
• Age older than 12 years.
• Staying in Belém (study area) until the end of the follow-up period (180 days).
Exclusion criteria
• Pregnant and nursing mothers were excluded.
• Patients who used antimalarials at least 2 weeks prior to the start of current
treatment.
• Carriers of mixed malaria.
Diagnosis: microscopy
G6PD status not stated
No details CYP2D6 status.
Interventions • Chloroquine 10 mg/kg single dose + primaquine 0.5 mg/kg/day for 7 days.
• Chloroquine 150 mg (25 mg/kg total dose) over 3 days, 10 mg/kg day 1, 7.5 mg/
kg days 2 and 3 + primaquine 15 mg/day 14 days.
(Additional arm chloroquine 10 mg/kg + primaquine 0.5 mg/kg for 5 days not included
as total dose (150 mg) less than standard treatment (210 mg))
Although different doses of chloroquine in the 2 arms, all participants had negative
parasitaemia within 72 hours
Primaquine and chloroquine given concurrently.
Supervised treatment.
Outcomes • Relapse.
• Safety.
Follow-up 180 days
Notes Location: Belém, state of Pará, Brazil
Setting: not stated
Source of funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details supplied on randomization process.
Allocation concealment (selection bias) Unclear risk No details supplied on allocation.
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Abdon 2001 BRA (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One loss to follow-up as moved out of area.
Selective reporting (reporting bias) Low risk Unable to find protocol but relapse and standard errors
(SEs) reported as would be expected
Other bias Unclear risk Funding not stated.
Bunnag 1994 THA
Methods RCT
Dates not provided.
Participants 167 participants enrolled.
Inclusion criteria:
• 15 to 60 years.
Exclusion criteria:
• History of previous treatment.
• G6PD deficiency.
• Mixed infections.
Diagnosis: microscopy
No details on pregnant/breastfeeding women.
No details CYP2D6 status.
Interventions • Chloroquine + 22.5 mg/day primaquine for 14 days.
• Chloroquine + 15 mg/day primaquine for 14 days.
Open randomization to chloroquine treatment - either 300 mg or 450 mg on day 1 of
admission. Re-allocated after recovery of acute symptoms (double-blind RCT). Chloro-
quine course completed and parasitological clearance confirmed prior to randomization
to primaquine group (exact time between treatment courses not specified)
Supervised treatment in hospital.
Outcomes • Relapse.
• Safety.
Follow-up 6 months
Notes Location: Thailand
Setting: not stated
Funding: not stated
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Bunnag 1994 THA (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 1st step chloroquine is open randomization, then PQ stage
randomized. No details on randomization process
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double-blind.
Incomplete outcome data (attrition bias)
All outcomes
High risk Unexplained high loss to follow-up.
Selective reporting (reporting bias) Unclear risk No protocol.
Other bias Unclear risk Funding not disclosed.
Carmona-Fonseca 2009 COL
Methods RCT
September 2003 to September 2006
Participants 133 patients enrolled across 2 arms (total 188 counting arms not included in review)
Inclusion criteria:
• Age > 2 years.
• P vivax parasitaemia of > 1000 asexual forms/L.
• Willingness to participate.
• A normal quantitative G6PD screening test was required for those administered >
0.25 mg/kg/day primaquine base, and only individuals with normal G6PD levels were
included in the study.
Exclusion criteria:
• Pregnant women.
• Those with associated acute infectious diseases.
• A history of antimalarials intake during the previous 2 weeks.
• Presence of diarrhoea or vomiting (> 5 episodes in 24 hours).
• Symptoms or signs of severe malaria (according to WHO 2006).
• Hypersensitivity to antimalarials or severe undernutrition.
• Exclusion from the study also followed intake of any antimalarial different from
those provided by the researchers.
• Failure to attend follow-up appointments.
• Treatment failure during the primary episode (first 28 days of follow-up).
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Carmona-Fonseca 2009 COL (Continued)
• Consent withdrawal.
Diagnosis: microscopy
No details CYP2D6 status or breastfeeding mothers.
Interventions • Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 1.17 mg/
kg/day for 3 days (total 210 mg).
• Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 0.25 mg/
kg/day for 14 days.
(Additional arms: 0.83 mg/kg day for 3 days (total dose 149.4 mg) and 0.58 mg/kg day
for 3 days (total dose 104.4 mg) not included as total dose less than standard treatment)
Primaquine given simultaneously with chloroquine.
Supervised treatment.
Outcomes • Recurrence of P vivax malaria (parasitaemia after day 28).
Follow-up 120 days
Notes Location: Colombia
Setting: patients that attended the local health clinics in Turbo and El Bagre
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details of randomization not given.
Allocation concealment (selection bias) Unclear risk No details supplied.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention on blinding in blood smear
assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 lost per group, no explanations given, but
less than 5% of total across groups
Selective reporting (reporting bias) Unclear risk Protocol not found. No safety data were
provided (which might have been expected
to have been provided)
Other bias Low risk Looks like government funding.
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Chu 2016 THA
Methods RCT
Participants 680 enrolled.
G6PD normal.
No further details
Interventions • Chloroquine + primaquine 7 days (1 mg/kg/day).
• Chloroquine + primaquine 14 days (0.5 mg/kg/day).
• Dihydroartemisinin-piperaquine + primaquine 7 days (1 mg/kg/day).
• Dihydroartemisinin-piperaquine + primaquine 14 days (0.5 mg/kg/day).
No further details
Outcomes • Relapse.
Follow-up: 1 year
Notes Location: Thailand
Setting: no details
Funding: no details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details.
Selective reporting (reporting bias) Unclear risk No details.
Other bias Unclear risk No details.
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Durand 2014 PER
Methods RCT
March 2006 to August 2008
Participants 360 participants
Inclusion criteria:
• Microscopy-confirmed diagnosis of monoinfection with P vivax between 250 and
100,000 asexual parasites/mL (determined by microscopic examination of thick and
thin peripheral blood smears).
• Fever defined as axillary temperature 37.5 °C or history of fever, or both.
• > 1 year old.
Exclusion criteria:
• Pregnant and lactating women.
• Patients with chronic illnesses.
• Patients with symptoms of severe malaria.
• Patients with G6PD deficiency.
Diagnosis: light microscopy
Parasite genotyping with PCR also performed - 5 microsatellite loci used to determine
whether homologous relapse
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/
day 7 days.
• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/
day for 14 days.
(Additional arm of chloroquine + primaquine 0.5 mg/kg/day for 5 days excluded as total
dose 150 mg, which was less than standard treatment.)
Supervised.
Primaquine administered concurrently with chloroquine.
Outcomes • Relapse between days 35 and 210.
• Relapses (homologous only).
Follow-up: 210 days
Notes Location: Peru
Setting: Padre Cocha and the San Juan Health Centers and Santa Clara Health Center
The periphery of the city of Iquitos, which is located on the river bank of the Amazon
River and is the largest city in the Peruvian rainforest
Funding: the US Department of Defense Global Emerging Infections Surveillance and
Response System (DoD-GEIS), the National Institute of Health of Peru, and the Pan-
AmericanHealthOrganization/US Agency for International Development (PAHO-US-
AID) Americas Malaria Initiative/Amazonic Network of Antimalarial Drug Resistance,
AMI/RAVREDA project
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomization table.
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Durand 2014 PER (Continued)
Allocation concealment (selection bias) Low risk The treatment allocation for each participant was
placed in a sealed envelope, kept in anorderlyman-
ner, and opened only at the time of enrolment of a
new participant to prevent selection bias by study
physicians
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label - no mention of blood smear blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8% to 10% loss following randomization, but all
accounted for
Selective reporting (reporting bias) Low risk Study protocol registered.Unable to findoutcomes
in protocol, but expected outcomes were reported
on
Other bias Low risk We did not detect any other sources of bias.
Leslie 2008 PAK
Methods RCT
September 2004 to July 2006
Participants 129 Afgan refugees
Inclusion criteria:
• Patients diagnosed with P vivax parasitaemia at study basic health units (BHUs).
• Patients over 3 years of age.
• Patient permanently resident in the village.
Exclusion criteria:
• Pregnancy or lactation.
• Severe clinical anaemia (7 g/dL).
• P falciparum or P vivax (mixed infections), or both.
• Intake of any antimalarial drug in the 2 weeks prior to consultation.
• Patients unavailable for the duration of follow-up (11 months).
• Patients with concomitant infections or disease likely to mask treatment response.
Diagnosis: microscopy
Interventions • Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.75 mg/kg
once weekly for 8 weeks.
• Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.5 mg/kg/
day for 14 days.
(Additional arm chloroquine + weekly placebo not included)
Supervised.
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Leslie 2008 PAK (Continued)
Not specified whether primaquine given concurrently with chloroquine
Outcomes • P vivax malaria relapse.
• The number of subsequent episodes and anaemia rates during and up to 2 weeks
post-treatment as well as any notable adverse events.
Follow-up: 9 months (11 months participation: 8 weeks treatment + 9 months follow-
up)
Notes Location: Pakistan
Setting: Adizai, Baghicha, and Khagan villages, close to Peshawar, Northwest Frontier
Province, Pakistan where Afghan refugees have been resident for more than 20 years
Funding: UNDP/World Bank/WHO Special Program for Research in Tropical Diseases;
Gates Malaria Partnership)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Two randomization methods were used. In
Baghicha and Khagan villages, participants were
randomized by household, whereas inAdizai, ran-
domization was at the individual level. Random-
ization lists for each village were generated us-
ing a random number list (MS Excel, Microsoft
Corp, Seattle, USA) by staff not involved in pa-
tient recruitment. Participants were randomized
on enrolment by study staff in the BHUs based
on house number or sequential patient numbers,
depending on the study site
Allocation concealment (selection bias) High risk Participants were randomized on enrolment by
study staff in the BHUs based on house number
or sequential patient numbers, depending on the
study site
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blood slides were double-read by 2 microscopists
working independently, who were blinded to the
other’s result
Incomplete outcome data (attrition bias)
All outcomes
High risk Higher loss to follow-up in intervention group
(6% to 8% versus 1% to 1.8%)
Selective reporting (reporting bias) Low risk Trial protocol available, all planned outcomes re-
ported on.
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Leslie 2008 PAK (Continued)
Other bias Low risk We did not detect any other sources of bias.
Pareek 2015 IND
Methods RCT
Participants 358 participants
Inclusion criteria:
• Patients of either sex.
• Aged between 18 and 65 years.
• Body weight > 40 kg.
• Microscopically confirmed P vivax malaria with ≥ 1000 asexual parasites/µL of
blood.
• Axillary temperature ≥ 37.5°C (≥ 99.5°F).
• Presence of at least 5 of the following signs and symptoms of uncomplicated
malaria: chills, nausea, vomiting, headache, malaise, diarrhoea, anorexia, abdominal
cramps, myalgia, and arthralgia.
Exclusion criteria:
• Mixed malarial infections.
• Severe or complicated malaria (as defined by the WHO).
• G6PD deficiency.
• Any other significant concomitant illness.
• Patients with history of dark urine or significant haemoglobinuria related to
previous primaquine treatment or those with history of methaemoglobinaemia.
• Patients with protracted vomiting and oliguria.
• Those with underlying condition compromising bone marrow function or having
a tendency to granulocytopenia.
• Patients taking cardioactive drug or potentially haemolytic drugs or drugs that
could interact with study drugs.
• Patients having history of hypersensitivity to any of the study-related drugs.
• Those on another investigational drug.
• History/presence of substance abuse.
• Pregnant or lactating women or women of childbearing potential not using
medically accepted means of birth control.
Diagnosis: microscopy
Interventions • Chloroquine (3-day course, dose not specified) + primaquine 30 mg sustained
release 7 days.
• Chloroquine (3-day course, dose not specified) + primaquine 15 mg 14 days.
(Additional arm of chloroquine + primaquine 15 mg sustained release for 14 days not
included in review)
Primaquine given following completion of chloroquine course.
Not supervised.
Outcomes • Relapse.
• Compliance.
• Safety.
PCR genotyping done to see if true relapse (no details on genotyping method)
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Pareek 2015 IND (Continued)
Follow-up: 5 months (6 months participation)
Notes Location: India
Setting: multicentre, no details as to centres involved
Funding: funded by drug manufacturer Ipca Laboratories Ltd. Anil Pareek and Nitin
Chandurkar are the employees of Ipca Laboratories Ltd who sponsored this trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization codes were generated using computer-generated
block randomization method
Allocation concealment (selection bias) Low risk Patient-specific sealed boxes of medicine were provided to each
study site
(Sequentially numbered, sealed, opaque envelopes (from proto-
col))
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details as to whether microscopy was blinded or whether
there was double reading of smears
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up equal between groups. Relapses counted as
discontinued patients, but numbers provided so can be assessed
Selective reporting (reporting bias) High risk Compliance added as an outcome, but original outcomes also
reported on.Not clear why they have concluded that compliance
increased with SR, as participants had to take 3 sets of pills as
did those who took dummy versions, so all participants took 3
sets of drugs
No measurement of levels of PQ (pharmacokinetics), although
states that PQ SR should have therapeutic concentration over
24 hours as part of the concept
PCR results are not well-detailed.
Other bias High risk The study was sponsored by Ipca Laboratories Ltd, who manu-
factures the drugs, and the principal investigators are employees
of the company
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Rajgor 2014 IND
Methods RCT
August 2001 to February 2004
Participants 1159 participants enrolled.
Inclusion criteria:
• Adult patients, male and female (18 years of age or older).
• Peripheral blood smear diagnosis of P vivax.
• Willing to undergo hospitalization for the entire duration of primaquine
treatment.
• Willing to provide informed consent.
• Willing to undergo investigations and come for regular follow-up.
• Normal G6PD.
• Haemoglobin ≥ 10 g/dL.
Exclusion criteria:
• Mixed infection with P falciparum.
• Pregnancy and lactation.
• Evidence of significant hepatic, renal, or cardiac disease as diagnosed by history,
clinical examination, and laboratory tests whenever necessary.
• Any other condition that would interfere with patient’s participation in the study
or compliance with the treatment.
Diagnosis: microscopy
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 7
days.
• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 14
days.
• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 15 mg/day 14
days.
(Additional no-primaquine arm not included in analysis)
Supervised treatment.
Primquine treatment commenced after chloroquine treatment (day 4)
Outcomes • Recurrence of vivax malaria.
• Safety.
Follow-up: 6 months
The secondary outcome also included comparison of number of participants classified
as relapse and re-infection by the 3 methods to determine the concordance between the
methods used and the genetic diversity observed based on PCR sequencing method. The
cases of recurrence were classified as relapse or re-infection based on the 3 methods, the
month of recurrence, and the 2 genotyping methods: PCR-RFLP and PCR sequencing
Notes Location: Mumbai, India
Setting: inpatient assessment in Mumbai
Funding: Indian Council of Medical Research
Risk of bias
Bias Authors’ judgement Support for judgement
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Rajgor 2014 IND (Continued)
Random sequence generation (selection
bias)
Low risk A simple, computer-generated randomization
scheme was used for the randomization of par-
ticipants into the 3 PQ regimen groups
Allocation concealment (selection bias) High risk This was an open-label study, and no conceal-
ment of treatment allocation was followed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Although the study was not blinded in terms
of treatment administration, the person seeing
the slides and carrying out other outcome as-
sessments was blinded to the treatment group
by coding of the samples
Incomplete outcome data (attrition bias)
All outcomes
High risk High percentage of participants not completing
6 months’ follow-up across all groups. Minimal
explanation for discontinuation of participants
Selective reporting (reporting bias) Unclear risk No registered protocol found - reported on ex-
pected outcomes of efficacy and adverse effects.
Trial carried out 2001 to 2004 but not published
until 2014
Other bias Low risk We did not detect any other sources of bias.
Saravu 2018 IND
Methods RCT, open-label, pilot study
March 2017 to August 2017
Participants 50 participants enrolled.
Patients presenting to Kasturba Hospital, Manipal and Dr TMA Pai Hospital, Udupi,
India
Inclusion criteria:
• P vivax malaria monoinfection.
• Age 18 years and over.
• Fever > 37.5°C tympanic or oral, or a history of fever within previous 3 days.
• Willing to give informed consent.
Exclusion criteria:
• Pregnant or lactating, or both.
• Patients with G6PD deficiency.
• Mixed infection with P vivax and P falciparum.
Primaquine given after blood-stage treatment.
Diagnosis: microscopy, but PCR also performed to genotype recurrences
No details CYP2D6
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Saravu 2018 IND (Continued)
Interventions Blood-stage treatment: either CQ or ACT (artesunate with doxycycline or artemether-
lumefantrine as per the treating clinician’s judgement of severity)
• Primaquine 0.5 mg/kg/day for 14 days
• Primaquine 0.25 mg/kg/day for 14 days
Drug therapy not supervised.
Outcomes 1. Recurrence
(2. Primaquine levels in the blood at 7 days)
Follow-up 6 months
Notes Location: Udupi district of Karnataka State, India
Setting: typical tropical climatic conditions. Malaria incidence throughout the year with
peaks around June to July. Urban and rural settings in catchment area
Source of funding: seedGrantAward fromManipalMcGill Center for InfectiousDiseases
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization - 5 blocks of 10, ran-
domization within each block done by a
lottery method
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
High risk High percentage of loss to follow-up by 6
months in both arms - results difficult to
interpret
Selective reporting (reporting bias) Low risk Outcomes reported as per protocol.
Other bias Low risk Supported by a seed Grant Award from
Manipal McGill Center for Infectious Dis-
eases, MAHE, Manipal
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Solari-Soto 2002 PER
Methods RCT
October 1998 to January 1999
Participants 60 participants enrolled.
Inclusion criteria:
• Confirmed diagnosis of P vivax malaria (febrile and positive P vivax blood smear).
Exclusion criteria:
• Patients who had received antimalarial medication in the 4 weeks prior to
diagnosis.
• Children under 5 years.
• Patients with severe concomitant diseases.
No details about inclusion/exclusion ofG6PD-deficient/pregnant/breastfeeding patients
Diagnosis: microscopy
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/
day for 14 days.
• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/
day for 7 days.
Directly observed therapy.
Primaquine given after chloroquine course.
Outcomes • Relapse.
• Adverse events.
Follow-up: 60 days (total enrolment 60 days)
Notes Location: Peru
Setting: patients treated at San Martín de Pangoa Hospital, Junín
Funding: US Naval Medical Research Institute Detachment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on randomization process.
Allocation concealment (selection bias) Unclear risk No details on allocation process.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Samples double-checked, but no details as to
whether blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data accounted for, similar in each
group.
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Solari-Soto 2002 PER (Continued)
Selective reporting (reporting bias) Unclear risk No details.
Other bias Low risk We did not detect any other sources of bias.
Abbreviations: ACT: artemisinin-based combination therapy; CQ: chloroquine; CYP2D6: cytochrome P450 2D6; G6PD: glucose-
6-phosphate dehydrogenase; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length
polymorphism; PQ: primaquine; RCT: randomized controlled trial; SE: standard error; SR: sustained release; WHO:World Health
Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adak 2001 No PQ comparison group.
Alvarez 2006 Comparison regimens are of a lower total dose than the control (15 mg/day for 3 days or 7 days) - shown
to be inferior in Galappaththy 2013.
Alvarez Sanchez 2007 Low-dose, shorter regimens of PQ.
Betuela 2012 Only one treatment group received primaquine.
Chu 2017 Wrong outcomes: primary outcome of this analysis was the fractional haematocrit reduction up to day 14
after enrolment
Chu 2018 No primaquine comparison arm.
Clyde 1977 Not an RCT, observational single-arm trial.
Contacos 1974 Not an RCT.
da Silva 1984 Not properly randomized (randomized according to whether the end of the notes code is odd or even),
low-dose comparison PQ group
Gogtay 1999 Low-dose 15 mg for shorter time period (5 days) - shown to be ineffective in Galappaththy 2013.
Goller 2007 Not an RCT - logistic regression using already-published RCTs and observational studies (not primary
trial)
Kim 2012 Wrong comparator: low-dose for 5 days - shown to be ineffective in Galappaththy 2013.
Kimura 1996 Not an RCT.
47Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Krudsood 2008 Artesunate only as blood-stage treatment (does not meet inclusion criteria) and follow-up only 28 days
Leslie 2004 No PQ comparison group: supervised versus unsupervised therapy
Leslie 2008b Duplicate of Leslie 2008 PAK; conference abstract title only for session at ASTMH 57th Annual Meeting
Maneeboonyang 2011 Not randomized, participants were sequentially allocated into either the directly observed therapy (DOT)
group or the self-administered therapy (SAT) group. No PQ comparison group, supervised versus non-
supervised therapy
Miller 1974 Not an RCT.
Pasaribu 2013 No PQ comparison group.
Pukrittayakamee 2000 No PQ comparison group.
Sabchareon 1981 No blood-stage antimalarial treatment used in primaquine comparison group according to inclusion
criteria
Saint-Yves IF 1977 Presumptive treatment of 45 mg PQ given to all participants before randomization
Takeuchi 2010 No PQ comparison group: supervised versus non-supervised therapy
Villalobos-Salcedo 2000 Wrong comparator: lower dose of PQ in comparison group (total dose 150 mg) - shown to be ineffective
in Galappaththy 2013.
Warrasak 2018 No primaquine comparison arm, ophthalmological outcomes.
Abbreviations: PQ: primaquine; RCT: randomized controlled trial.
Characteristics of ongoing studies [ordered by study ID]
NCT01814683
Trial name or title Improving the radical cure of vivax malaria: a multicentre randomised comparison of short and long course
primaquine regimens
Methods RCT, multicentre
Participant, care provider, and investigator blinding
Participants Aged 6 months and older.
Inclusion criteria:
• Participant (or parent/guardian of children below age of consent) is willing and able to give written
informed consent to participate in the trial; verbal consent in the presence of a literate witness is required for
illiterate patients. In addition, written assent (or verbal assent in the presence of a literate witness for
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NCT01814683 (Continued)
illiterates) from children 12 to 17 years as per local practice.
• Monoinfection with P vivax of any parasitaemia in countries that use chloroquine as blood
schizonticidal therapy. Mixed infections with P vivax and P falciparum can be enrolled in countries that use
an artemisinin combination therapy.
• Diagnosis based on rapid diagnostic tests.
• Over 6 months of age.
• Weight 5 kg or greater.
• Fever (axillary temperature 37.5°C) or history of fever in the last 48 hours.
• Able (in the investigator’s opinion) and willing to comply with the study requirements and follow-up.
Exclusion criteria:
• Female participant who is pregnant, lactating, or planning pregnancy during the course of the study.
• Inability to tolerate oral treatment.
• Previous episode of haemolysis or severe haemoglobinuria following primaquine.
• Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral
treatment - haemoglobin concentration less than 9 g/dL.
• Known hypersensitivity or allergy to the study drugs.
• Blood transfusion in last 90 days, since this can mask G6PD-deficient status.
• A febrile condition due to diseases other than malaria (for example, measles, acute lower respiratory
tract infection, severe diarrhoea with dehydration).
• Presence of any condition which in the judgement of the investigator would place the participant at
undue risk or interfere with the results of the study (for example, serious underlying cardiac, renal, or
hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than malaria); co-
administration of other medication known to cause haemolysis or that could interfere with the assessment
of antimalarial regimens.
• Currently taking medication known to interfere significantly with the pharmacokinetics of primaquine
and the schizonticidal study drugs.
• Prior antimalarial medications in the previous 7 days.
Locations: Afghanistan, Ethiopia, Indonesia, Vietnam
Estimated enrolment: 3150 participants
Interventions 1. Standard blood schizonticidal therapy plus 7 days of supervised primaquine (7 mg/kg total dose) admin-
istered once per day (1.0 mg/kg once daily) followed by 7 days of placebo
2. Standard blood schizonticidal therapy plus 14 days of supervised primaquine (7 mg/kg total dose) admin-
istered once per day (0.5 mg/kg)
(3. Standard blood schizonticidal therapy plus 14 days placebo)
Outcomes • Incidence rate (per person-year) and risk of symptomatic recurrent P vivax [Time Frame: 12 months].
The incidence rate (that is, per person-year) of symptomatic recurrent P vivax parasitaemia (detected by
microscopy) over 12 months of follow-up in the 7- versus 14-day primaquine groups for all sites combined
and stratified by site
• Incidence rate (per person-year) of recurrent P vivax parasitaemia; haematological recovery; serious
adverse drug reaction, primaquine tolerability, risk of severe anaemia in G6PD-deficient arm, cost-effective
analysis with respect to the use of G6PD tests
Starting date July 2014
Contact information Ric Price, University of Oxford; ric.price@ndm.ox.ac.uk
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NCT01814683 (Continued)
Notes Esimated completion date: December 2019
Protocol published (see IMPROV Study Group 2015; listed under NCT01814683)
clinicaltrials.gov/ct2/show/NCT01814683
NCT01837992
Trial name or title Evaluation of safety and efficacy of two primaquine dosing regimens for the radical treatment of Plasmodium
vivax malaria in Vanuatu and Solomon Islands
Methods RCT, open-label
Participants Children and adults aged 12 months to 60 years. Solomon Islands and Vanuatu
Inclusion criteria:
• Age 12 months to 60 years.
• Melanesian background and living in local area.
• Microscopically (based on field microscopy) or RDT-confirmed P vivax regardless of parasite density.
Mixed infections (P falciparum-P vivax and P malariae-P vivax) can be included.
Exclusion criteria:
• Any signs of severe malaria (see WHO definitions) including: impaired consciousness, respiratory
distress, severe anaemia (haemoglobin < 5), multiple seizures, frequent vomiting/inability to swallow tablets,
prostration, jaundice, hypotension, abnormal bleeding, or hypoglycaemia.
• Clinical evidence of non-malarial illness (such as pneumonia or otitis media).
• Severe malnutrition (weight-for-age nutritional Z score < 60th percentile).
• Permanent disability that prevents or impedes study participation.
• Treatment with primaquine in the previous 14 days.
• Residence or planned travel outside the study area during the follow-up period (precluding supervised
treatment and follow-up procedures).
• Known or suspected pregnancy.
• Currently breastfeeding.
• A positive rapid test for G6PD deficiency (Binax or Carestart RDT).
Interventions 1. Primaquine dose of 0.5 mg/kg/day for 14 consecutive days and standard age-based dosage 3-day course of
artemether-lumefantrine
2. Primaquine dose of 0.25 mg/kg for 14 consecutive days and standard age-based dosage 3-day course of
artemether-lumefantrine
(3. Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard
age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or
completion of 3 months follow-up)
Outcomes • Efficacy: numbers of P vivax relapses per person-years of follow-up [Time Frame: 12 months]. Total
number of microscopically diagnosed (including both symptomatic and asymptomatic infections), PCR-
confirmed relapses with P vivax in participants in each treatment arm over the 3-month follow-up period,
expressed as number of relapses per person-years of follow-up.
• Safety and toxicity: mild, moderate, and severe adverse events, haemolysis, methaemoglobinaemia.
Starting date May 2013
Contact information Dr Ivo Mueller; mueller@wehi.edu.au
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NCT01837992 (Continued)
Notes Estimated completion date May 2015. Contacted for results - no response
Protocol available at clinicaltrials.gov/ct2/show/NCT01837992
Abbreviations: G6PD: glucose-6-phosphate dehydrogenase; RCT: randomized controlled trial; RDT: rapid diagnostic test; WHO:
World Health Organization.
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D A T A A N D A N A L Y S E S
Comparison 1. High-standard 14-day regimen versus standard 14-day regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence at 6 months’
follow-up
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months (chloroquine
blood-stage treatment)
1 639 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.47, 1.43]
1.2 6 months (chloroquine or
ACT blood-stage treatment)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.17, 7.09]
2 Recurrence (PCR-adjusted) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 6 to 7 months 1 639 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.62, 5.40]
3 Serious adverse effects 1 778 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events that result in
discontinuation of treatment
1 778 Risk Ratio (M-H, Fixed, 95% CI) 4.19 [0.90, 19.60]
5 Adverse effects known to occur
with primaquine
1 778 Risk Ratio (M-H, Fixed, 95% CI) 2.72 [0.98, 7.57]
6 Adverse events known to occur
with chloroquine
1 778 Risk Ratio (M-H, Fixed, 95% CI) 9.43 [0.51, 174.47]
Comparison 2. 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence by 6 to 7 months’
follow-up
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
2 Recurrence by 6 to 7 months’
follow-up (PCR-adjusted)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Recurrence by 6 to 7 months
subgrouped by geographical
region
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
3.1 South America 2 397 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.26]
3.2 Asia 2 814 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.73, 1.94]
4 Recurrence by 6 to 7 months
subgrouped by directly
observed therapy (DOT) versus
non-DOT
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
4.1 DOT 3 1017 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.67, 1.43]
4.2 Non-DOT 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.20]
5 Serious adverse effects 5 1427 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events that result in
discontinuation of treatment
5 1427 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.15, 7.38]
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7 Adverse effects known to occur
with primaquine
4 1154 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.64, 1.76]
8 Anaemia or change in
haemoglobin status
1 240 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.91]
9 Adverse events known to occur
with chloroquine
1 779 Risk Ratio (M-H, Fixed, 95% CI) 9.40 [0.51, 174.01]
Comparison 3. 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 5 months 1 129 Risk Ratio (M-H, Fixed, 95% CI) 5.23 [0.28, 99.15]
1.2 8 months 1 126 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 127.32]
1.3 11 months 1 122 Risk Ratio (M-H, Fixed, 95% CI) 3.18 [0.37, 27.60]
2 Serious adverse effects 1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Anaemia (haemoglobin < 7
g/dL)
1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. 0.375 mg/kg/day primaquine for 14 days versus standard 14-day regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months’ follow-up 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.01, 3.34]
1.2 12 months’ follow-up 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 18 months’ follow-up 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. 1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen; follow-up 4 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence 1 129 Risk Ratio (M-H, Fixed, 95% CI) 3.88 [2.11, 7.11]
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Analysis 1.1. Comparison 1 High-standard 14-day regimen versus standard 14-day regimen, Outcome 1
Recurrence at 6 months’ follow-up.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 1 High-standard 14-day regimen versus standard 14-day regimen
Outcome: 1 Recurrence at 6 months’ follow-up
Study or subgroup
0.5mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months (chloroquine blood-stage treatment)
Rajgor 2014 IND (1) 21/317 26/322 100.0 % 0.82 [ 0.47, 1.43 ]
Subtotal (95% CI) 317 322 100.0 % 0.82 [ 0.47, 1.43 ]
Total events: 21 (0.5mg/kg/day PQ 14 days), 26 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 6 months (chloroquine or ACT blood-stage treatment)
Saravu 2018 IND (2) 2/18 2/20 100.0 % 1.11 [ 0.17, 7.09 ]
Subtotal (95% CI) 18 20 100.0 % 1.11 [ 0.17, 7.09 ]
Total events: 2 (0.5mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
(1) Chloroquine used for blood stage treatment, treatment supervised
(2) Blood stage treatment is either chloroquine or an ACT, treatment unsupervised
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Analysis 1.2. Comparison 1 High-standard 14-day regimen versus standard 14-day regimen, Outcome 2
Recurrence (PCR-adjusted).
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 1 High-standard 14-day regimen versus standard 14-day regimen
Outcome: 2 Recurrence (PCR-adjusted)
Study or subgroup
0.5mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 to 7 months
Rajgor 2014 IND (1) 9/317 5/322 100.0 % 1.83 [ 0.62, 5.40 ]
Subtotal (95% CI) 317 322 100.0 % 1.83 [ 0.62, 5.40 ]
Total events: 9 (0.5mg/kg/day PQ 14 days), 5 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
(1) 6 months follow up
Analysis 1.3. Comparison 1 High-standard 14-day regimen versus standard 14-day regimen, Outcome 3
Serious adverse effects.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 1 High-standard 14-day regimen versus standard 14-day regimen
Outcome: 3 Serious adverse effects
Study or subgroup
0.5mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rajgor 2014 IND 0/380 0/398 Not estimable
Total (95% CI) 380 398 Not estimable
Total events: 0 (0.5mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
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Analysis 1.4. Comparison 1 High-standard 14-day regimen versus standard 14-day regimen, Outcome 4
Adverse events that result in discontinuation of treatment.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 1 High-standard 14-day regimen versus standard 14-day regimen
Outcome: 4 Adverse events that result in discontinuation of treatment
Study or subgroup
0.5mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rajgor 2014 IND 8/380 2/398 100.0 % 4.19 [ 0.90, 19.60 ]
Total (95% CI) 380 398 100.0 % 4.19 [ 0.90, 19.60 ]
Total events: 8 (0.5mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
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Analysis 1.5. Comparison 1 High-standard 14-day regimen versus standard 14-day regimen, Outcome 5
Adverse effects known to occur with primaquine.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 1 High-standard 14-day regimen versus standard 14-day regimen
Outcome: 5 Adverse effects known to occur with primaquine
Study or subgroup
0.5mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rajgor 2014 IND 13/380 5/398 100.0 % 2.72 [ 0.98, 7.57 ]
Total (95% CI) 380 398 100.0 % 2.72 [ 0.98, 7.57 ]
Total events: 13 (0.5mg/kg/day PQ 14 days), 5 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
Analysis 1.6. Comparison 1 High-standard 14-day regimen versus standard 14-day regimen, Outcome 6
Adverse events known to occur with chloroquine.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 1 High-standard 14-day regimen versus standard 14-day regimen
Outcome: 6 Adverse events known to occur with chloroquine
Study or subgroup
0.5mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rajgor 2014 IND 4/380 0/398 100.0 % 9.43 [ 0.51, 174.47 ]
Total (95% CI) 380 398 100.0 % 9.43 [ 0.51, 174.47 ]
Total events: 4 (0.5mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
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Analysis 2.1. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 1
Recurrence by 6 to 7 months’ follow-up.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 1 Recurrence by 6 to 7 months’ follow-up
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdon 2001 BRA (1) 0/39 2/40 4.8 % 0.21 [ 0.01, 4.14 ]
Durand 2014 PER (2) 16/156 22/162 42.2 % 0.76 [ 0.41, 1.38 ]
Pareek 2015 IND (3) 1/99 2/95 4.0 % 0.48 [ 0.04, 5.20 ]
Rajgor 2014 IND (4) 30/298 26/322 48.9 % 1.25 [ 0.76, 2.06 ]
Total (95% CI) 592 619 100.0 % 0.96 [ 0.66, 1.39 ]
Total events: 47 (0.5mg/kg/day PQ 7 days), 52 (0.25mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
(1) Follow up 180 days (6 months)
(2) Follow up 210 days (7 months)
(3) Follow up 6 months. Primaquine 30mg sustained release preparation used.
(4) 6 months follow up
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Analysis 2.2. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 2
Recurrence by 6 to 7 months’ follow-up (PCR-adjusted).
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 2 Recurrence by 6 to 7 months’ follow-up (PCR-adjusted)
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Durand 2014 PER (1) 8/156 12/162 0.69 [ 0.29, 1.65 ]
Rajgor 2014 IND (2) 12/298 5/322 2.59 [ 0.92, 7.27 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
(1) Follow up 210 days (7 months)
(2) Follow up 6 months
59Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.3. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 3
Recurrence by 6 to 7 months subgrouped by geographical region.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 3 Recurrence by 6 to 7 months subgrouped by geographical region
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 South America
Abdon 2001 BRA 0/39 2/40 4.8 % 0.21 [ 0.01, 4.14 ]
Durand 2014 PER 16/156 22/162 42.2 % 0.76 [ 0.41, 1.38 ]
Subtotal (95% CI) 195 202 47.1 % 0.70 [ 0.39, 1.26 ]
Total events: 16 (0.5mg/kg/day PQ 7 days), 24 (0.25mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 Asia
Pareek 2015 IND 1/99 2/95 4.0 % 0.48 [ 0.04, 5.20 ]
Rajgor 2014 IND 30/298 26/322 48.9 % 1.25 [ 0.76, 2.06 ]
Subtotal (95% CI) 397 417 52.9 % 1.19 [ 0.73, 1.94 ]
Total events: 31 (0.5mg/kg/day PQ 7 days), 28 (0.25mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 592 619 100.0 % 0.96 [ 0.66, 1.39 ]
Total events: 47 (0.5mg/kg/day PQ 7 days), 52 (0.25mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 1.86, df = 1 (P = 0.17), I2 =46%
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ Favours 0.25mg/kg/day PQ
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Analysis 2.4. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 4
Recurrence by 6 to 7 months subgrouped by directly observed therapy (DOT) versus non-DOT.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 4 Recurrence by 6 to 7 months subgrouped by directly observed therapy (DOT) versus non-DOT
Study or subgroup
0.5
mg/kg/day
PQ 7 days
0.25
mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DOT
Abdon 2001 BRA 0/39 2/40 4.8 % 0.21 [ 0.01, 4.14 ]
Durand 2014 PER 16/156 22/162 42.2 % 0.76 [ 0.41, 1.38 ]
Rajgor 2014 IND 30/298 26/322 48.9 % 1.25 [ 0.76, 2.06 ]
Subtotal (95% CI) 493 524 96.0 % 0.98 [ 0.67, 1.43 ]
Total events: 46 (0.5 mg/kg/day PQ 7 days), 50 (0.25 mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 2.64, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.12 (P = 0.91)
2 Non-DOT
Pareek 2015 IND 1/99 2/95 4.0 % 0.48 [ 0.04, 5.20 ]
Subtotal (95% CI) 99 95 4.0 % 0.48 [ 0.04, 5.20 ]
Total events: 1 (0.5 mg/kg/day PQ 7 days), 2 (0.25 mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 592 619 100.0 % 0.96 [ 0.66, 1.39 ]
Total events: 47 (0.5 mg/kg/day PQ 7 days), 52 (0.25 mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.56), I2 =0.0%
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Favours 0.5mg/kg/day PQ Favours 0.25mg/kg/day PQ
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Analysis 2.5. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 5 Serious
adverse effects.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 5 Serious adverse effects
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdon 2001 BRA 0/40 0/40 Not estimable
Durand 2014 PER 0/156 0/162 Not estimable
Pareek 2015 IND (1) 0/99 0/95 Not estimable
Rajgor 2014 IND (2) 0/381 0/398 Not estimable
Solari-Soto 2002 PER 0/28 0/28 Not estimable
Total (95% CI) 704 723 Not estimable
Total events: 0 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
(1) Primaquine 30mg sustained release preparation used.
(2) 6 months follow up
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Analysis 2.6. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 6 Adverse
events that result in discontinuation of treatment.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 6 Adverse events that result in discontinuation of treatment
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdon 2001 BRA 0/40 0/40 Not estimable
Durand 2014 PER 0/156 0/162 Not estimable
Pareek 2015 IND (1) 0/99 0/95 Not estimable
Rajgor 2014 IND 2/381 2/398 100.0 % 1.04 [ 0.15, 7.38 ]
Solari-Soto 2002 PER 0/28 0/28 Not estimable
Total (95% CI) 704 723 100.0 % 1.04 [ 0.15, 7.38 ]
Total events: 2 (0.5mg/kg/day PQ 7 days), 2 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
(1) Primaquine 30mg sustained release preparation used.
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Analysis 2.7. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 7 Adverse
effects known to occur with primaquine.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 7 Adverse effects known to occur with primaquine
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdon 2001 BRA 6/39 11/40 42.2 % 0.56 [ 0.23, 1.36 ]
Pareek 2015 IND (1) 11/120 10/120 38.8 % 1.10 [ 0.49, 2.49 ]
Rajgor 2014 IND 10/381 5/398 19.0 % 2.09 [ 0.72, 6.06 ]
Solari-Soto 2002 PER 0/28 0/28 Not estimable
Total (95% CI) 568 586 100.0 % 1.06 [ 0.64, 1.76 ]
Total events: 27 (0.5mg/kg/day PQ 7 days), 26 (0.25mg/kg/day PQ 14 days)
Heterogeneity: Chi2 = 3.54, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
(1) Primaquine 30mg sustained release preparation used.
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Analysis 2.8. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 8 Anaemia
or change in haemoglobin status.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 8 Anaemia or change in haemoglobin status
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pareek 2015 IND (1) 1/120 0/120 100.0 % 3.00 [ 0.12, 72.91 ]
Total (95% CI) 120 120 100.0 % 3.00 [ 0.12, 72.91 ]
Total events: 1 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
(1) Primaquine 30mg sustained release preparation used.
Analysis 2.9. Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome 9 Adverse
events known to occur with chloroquine.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome: 9 Adverse events known to occur with chloroquine
Study or subgroup
0.5mg/kg/day
PQ 7 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rajgor 2014 IND 4/381 0/398 100.0 % 9.40 [ 0.51, 174.01 ]
Total (95% CI) 381 398 100.0 % 9.40 [ 0.51, 174.01 ]
Total events: 4 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen,
Outcome 1 Recurrence.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 3 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen
Outcome: 1 Recurrence
Study or subgroup
0.75mg/kg
PQ weekly
8wks
0.5mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 months
Leslie 2008 PAK 3/74 0/55 100.0 % 5.23 [ 0.28, 99.15 ]
Subtotal (95% CI) 74 55 100.0 % 5.23 [ 0.28, 99.15 ]
Total events: 3 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 8 months
Leslie 2008 PAK 4/71 0/55 100.0 % 7.00 [ 0.38, 127.32 ]
Subtotal (95% CI) 71 55 100.0 % 7.00 [ 0.38, 127.32 ]
Total events: 4 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
3 11 months
Leslie 2008 PAK 4/68 1/54 100.0 % 3.18 [ 0.37, 27.60 ]
Subtotal (95% CI) 68 54 100.0 % 3.18 [ 0.37, 27.60 ]
Total events: 4 (0.75mg/kg PQ weekly 8wks), 1 (0.5mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 0.20, df = 2 (P = 0.91), I2 =0.0%
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Analysis 3.2. Comparison 3 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen,
Outcome 2 Serious adverse effects.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 3 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen
Outcome: 2 Serious adverse effects
Study or subgroup
0.75mg/kg
PQ weekly
8wks
0.5mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leslie 2008 PAK 0/74 0/55 Not estimable
Total (95% CI) 74 55 Not estimable
Total events: 0 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 0.75mg/kg PQ weekly 8wks Favours 0.5mg/kg/day PQ 14 days
Analysis 3.3. Comparison 3 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen,
Outcome 3 Anaemia (haemoglobin < 7 g/dL).
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 3 0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen
Outcome: 3 Anaemia (haemoglobin < 7 g/dL)
Study or subgroup
0.75mg/kg
PQ weekly
8wks
0.5mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leslie 2008 PAK 0/74 0/55 Not estimable
Total (95% CI) 74 55 Not estimable
Total events: 0 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Favours 0.75mg/kg PQ weekly 8wks Favours 0.5mg/kg/day PQ 14 days
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Analysis 4.1. Comparison 4 0.375 mg/kg/day primaquine for 14 days versus standard 14-day regimen,
Outcome 1 Recurrence.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 4 0.375 mg/kg/day primaquine for 14 days versus standard 14-day regimen
Outcome: 1 Recurrence
Study or subgroup
0.375mg/kg/day
PQ 14 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months’ follow-up
Bunnag 1994 THA 0/40 2/33 100.0 % 0.17 [ 0.01, 3.34 ]
Subtotal (95% CI) 40 33 100.0 % 0.17 [ 0.01, 3.34 ]
Total events: 0 (0.375mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 12 months’ follow-up
Bunnag 1994 THA 0/24 0/25 Not estimable
Subtotal (95% CI) 24 25 Not estimable
Total events: 0 (0.375mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 18 months’ follow-up
Bunnag 1994 THA 0/19 0/19 Not estimable
Subtotal (95% CI) 19 19 Not estimable
Total events: 0 (0.375mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Favours 0.375mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
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Analysis 5.1. Comparison 5 1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen; follow-up
4 months, Outcome 1 Recurrence.
Review: Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
Comparison: 5 1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen; follow-up 4 months
Outcome: 1 Recurrence
Study or subgroup
1.17mg/kg/day
PQ 3 days
0.25mg/kg/day
PQ 14 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carmona-Fonseca 2009 COL (1) 37/63 10/66 100.0 % 3.88 [ 2.11, 7.11 ]
Total (95% CI) 63 66 100.0 % 3.88 [ 2.11, 7.11 ]
Total events: 37 (1.17mg/kg/day PQ 3 days), 10 (0.25mg/kg/day PQ 14 days)
Heterogeneity: not applicable
Test for overall effect: Z = 4.37 (P = 0.000012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 1.17mg/kg/day PQ 3 days Favours 0.25mg/kg/day PQ 14 days
(1) Follow up 120 days (4 months)
A D D I T I O N A L T A B L E S
Table 1. Data extraction: grouping of comparisons to address the review’s objectives
Objective Intervention Control
Are higher doses (0.5 mg/kg/day or 30 mg/
day primaquine for 14 days) more effective
in all areas, or only in areas where they are
standard treatment (East Asia andOceania)
?
Blood-stage antimalarial drug with pri-
maquine 0.5mg/kg/day (adult dose 30mg)
for 14 days (total dose 420 mg)
Both intervention and control groups must
have received the same treatment for the
blood-borne stage of infection, that is, ei-
ther CQ or ACT
Blood-stage antimalarial drug with stan-
dard 14-day course primaquine (0.25 mg/
kg/day, adult dose 15 mg, total dose 210
mg)
Both intervention and control groups must
have received the same treatment for the
blood-borne stage of infection, that is, ei-
ther CQ or ACT
Are shorter, higher-dose regimens of pri-
maquine over 7 days as effective as treat-
ment over 14 days (is the total dose rather
than the length of treatment the important
factor)?
Blood-stage antimalarial drug with pri-
maquine 0.5mg/kg/day (adult dose 30mg)
for 7 days (total dose 210 mg) or 1 mg/
kg/day (adult dose 60 mg) for 7 days (total
dose 420 mg)
Both intervention and control groups must
have received the same treatment for the
blood-borne stage of infection, that is, ei-
ther CQ or ACT
Blood-stage antimalarial drug with stan-
dard 14-day course primaquine (0.25 mg/
kg/day, adult dose 15 mg, total dose 210
mg) or high-standard 14-day course pri-
maquine (0.5mg/kg/day, adult dose 30mg,
total dose 420 mg)
Both intervention and control groups must
have received the same treatment for the
blood-borne stage of infection, that is, ei-
ther CQ or ACT
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Table 1. Data extraction: grouping of comparisons to address the review’s objectives (Continued)
Are weekly dosing regimens (0.75 mg/kg/
week or 45 mg/week for 8 weeks) as effec-
tive?
Blood-stage antimalarial drug with pri-
maquine 0.75/kg (45 mg) per week for 8
weeks (total dose 360 mg)
Blood-stage antimalarial drug with stan-
dard 14-day course primaquine (0.25 mg/
kg/day, adult dose 15 mg, total dose 210
mg) or high-standard 14-day course pri-
maquine (0.5mg/kg/day, adult dose 30mg,
total dose 420 mg)
Both intervention and control groups must
have received the same treatment for the
blood-borne stage of infection, that is, ei-
ther CQ or ACT
Abbreviations: ACT = artemisinin-based combination therapy; CQ = chloroquine.
A P P E N D I C E S
Appendix 1. Detailed search strategies
PubMed MEDLINE
1 primaquine [Title/Abstract]
2 “Primaquine”[Mesh]
3 1 or 2
4 “plasmodium vivax” [Title/Abstract]
5 “Plasmodium vivax”[Mesh]
6 “vivax malaria ” [Title/Abstract]
7 “Malaria, Vivax”[Mesh]
8 4 or 5 or 6
9 3 and 8
10 “Randomized Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
11 randomized or placebo [Title/Abstract]
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(Continued)
12 randomly or trial or groups [Title/Abstract]
13 “drug therapy” [Subheading]
14 10 or 11 or 12 or 13
15 9 and 14
Cochrane Library
Issue 12 2018
ID Search
#1 primaquine: ti,ab,kw: (Word variations have been searched)
#2 MeSH descriptor: [Primaquine] explode all trees
#3 #1 or #2
#4 “plasmodium vivax”: ti, ab,kw (Word variations have been searched)
#5 MeSH descriptor : [Malaria, Vivax] explode all trees
#6 MeSH descriptor: [Plasmodium vivax ] explode all trees
#7 #4 or #5 or #6
#8 #3 and #7
Embase
1947-Present, updated daily
--------------------------------------------------------------------------------
1 “primaquine”.mp.
2 primaquine/
3 1 or 2
4 plasmodium vivax.mp. or Plasmodium vivax/
5 malaria vivax.mp. or Plasmodium vivax malaria/
6 4 or 5 or 6
7 controlled clinical trial.mp. or Controlled Clinical Trial/
8 randomized controlled trial.mp. or Randomized Controlled Trial/
9 (randomized or placebo or double-blind* or single-blind*).mp.
10 randomization/
11 crossover procedure/
12 7 or 8 or 9 or 10 or 11
13 3 and 6 and 12
LILACS
Search on : primaquine [Words] and malaria vivax or plasmodium vivax [Words]
ClinicalTrials.gov and WHO ICTRP
primaquine and vivax
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We changed the inclusion criteria for trials to add 30 mg (0.5 mg/kg/day) for 14 days, as this is a World Health Organization-
recommended regimen, and some trials use it as the control group for this reason.
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